NAME,DESCRIPTION,SEQAPASS,GENE_SYMBOLS,GENE_NAMES,GENE_URLS,AOP,EVENT,HIT_CALL,TOP,SCALED_TOP,AC50,LOGAC50,BMAD,MAXMED,MAXMED_UNITS,MAXMEDCONC,CUTOFF,FLAGS,MODLACC,MODLAC10,MODLACB,STOCK_CONCENTRATION,INTENDED_TARGET_FAMILY
ACEA_AR_agonist_AUC_viability,"Data from the assay component ACEA_AR_AUC_viability was analyzed  in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,125.881141403321,4.684923281114503,32.222947238038984,1.50816526018872,8.95647120560566,135.644901747939,percent_activity,2,26.869413616817,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.43735271908015,1.43735271908015,1.38886981011567,20,cell cycle
ACEA_AR_antagonist_80hr,"Data from the assay component ACEA_AR_antagonist_80hr was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, measures of the cells for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/367,,,Active,2.15437179988243,5.885486723727829,35.773185280098005,1.55355761188452,0.122016065451132,2.15376714370551,log2_fold_induction,2,0.366048196353396,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.46716238000366,1.46716238000366,1.43388702839819,20,nuclear receptor
ACEA_AR_antagonist_AUC_viability,"Data from the assay component ACEA_AR_antagonist_AUC_viability was analyzed  in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,106.991349219476,3.6956288070630516,28.784829970164452,1.45916366845374,9.65026114229828,106.985428294781,percent_activity,2,28.9507834268948,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.4053006465729,1.4053006465729,1.33981574999918,20,cell cycle
ACEA_ER_AUC_viability,"Data from the assay component ACEA_ER_AUC_viability was analyzed  in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,44.4818823668608,2.2240941183430403,199.20086402851086,2.299291217832663,5.860768439731081,40.91356633616909,percent_activity,2.30102999566398,20,"[""Less than 50% efficacy"",""Borderline active"",""Only one conc above baseline, active""]",2.2883143232170937,2.2762074226881093,2.1800104345445392,30,cell cycle
APR_HepG2_CellCycleArrest_24h_dn,"Data from the assay component APR_HepG2_CellCycleArrest_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellCycleArrest_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""proliferation"".",, , , ,,,Active,1.12745218229925,1.600028024145008,110.39230649036345,2.04293880740397,0.070464527201123,0.939543485310557,log2_fold_induction,2.30102999566398,0.70464527201123,,2.14246426007736,1.75721831099012,1.61480882200276,20,cell cycle
APR_HepG2_CellCycleArrest_72h_dn,"Data from the assay component APR_HepG2_CellCycleArrest_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellCycleArrest_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""proliferation"".",, , , ,,,Active,1.02400538197592,1.1043170427376539,110.71114756938037,2.04419135244261,0.0927274815425616,1.01499605623267,log2_fold_induction,2.30102999566398,0.927274815425616,"[""Borderline active"",""Borderline active""]",2.16689694487679,1.99065310005083,1.92491103799584,20,cell cycle
APR_HepG2_CellLoss_24h_dn,"Data from the assay component APR_HepG2_CellLoss_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellLoss_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.814849869072711,1.2308506326254576,105.84794716202843,2.02468243963603,0.066202173316075,0.809801136460463,log2_fold_induction,2.30102999566398,0.66202173316075,,2.1042660573422,1.96321259566435,1.90540212395461,20,cell cycle
APR_HepG2_CellLoss_72h_dn,"Data from the assay component APR_HepG2_CellLoss_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellLoss_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,3.88863977371132,4.382161588172558,113.791317370551,2.0561091253111,0.0887379366431112,2.8668671472195,log2_fold_induction,2.30102999566398,0.887379366431112,,1.91893929257862,1.76223052548088,1.80876467672405,20,cell cycle
APR_HepG2_MitoMass_24h_dn,"Data from the assay component APR_HepG2_MitoMass_24hr was analyzed into 2 assay endpoints. This assay endpoint, APR_HepG2_MitoMass_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, loss-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""organelle conformation"".",, , , ,,,Active,0.846144016297311,1.7004845112783973,115.34885665464773,2.06201329412336,0.0497589957853361,0.705120013596573,log2_fold_induction,2.30102999566398,0.497589957853361,,2.11650783357433,1.82614615024298,1.72565809400187,20,cell morphology
APR_HepG2_MitoticArrest_24h_up,"Data from the assay component APR_HepG2_MitoticArrest_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_MitoticArrest_24h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""arrest"".",,H3F3A,"H3 histone, family 3A",https://www.ncbi.nlm.nih.gov/gene/3020,,,Active,1.38738088462195,1.2587082930610007,112.91285381809806,2.05274338412618,0.110222590275308,1.36239359263737,log2_fold_induction,2.30102999566398,1.10222590275308,,2.13669569659774,1.98060413943612,1.91631239390305,20,cell cycle
APR_HepG2_MitoticArrest_72h_up,"Data from the assay component APR_HepG2_MitoticArrest_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_MitoticArrest_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""arrest"".",,H3F3A,"H3 histone, family 3A",https://www.ncbi.nlm.nih.gov/gene/3020,,,Active,2.97904395359719,2.099299674186592,111.68753238919726,2.04800469579441,0.141906560088972,2.69476538915246,log2_fold_induction,2.30102999566398,1.41906560088972,,2.0373511421706,1.84642245104759,1.80075182090243,20,cell cycle
APR_HepG2_p53Act_24h_up,"Data from the assay component APR_HepG2_p53Act_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_p53Act_24h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene TP53. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""tumor suppressor"".",NP_000537.3,TP53,tumor protein p53,https://www.ncbi.nlm.nih.gov/gene/7157,"[46,46]",,Active,1.4139540977578942,1.4549028263829835,124.00401068704392,2.0934357318645214,0.09718546641861357,1.17829508150015,log2_fold_induction,2.30102999566398,0.9718546641861358,,2.1958788540590777,1.9181187226813134,1.8076686832890414,20,dna binding
APR_HepG2_p53Act_72h_up,"Data from the assay component APR_HepG2_p53Act_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_p53Act_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene TP53. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""tumor suppressor"".",NP_000537.3,TP53,tumor protein p53,https://www.ncbi.nlm.nih.gov/gene/7157,"[46,46]",,Active,1.85097097491527,1.5663657311792623,107.81957894142163,2.03269763148284,0.118169782322915,1.83781060314024,log2_fold_induction,2.30102999566398,1.18169782322915,,2.06356051062647,1.95451789430419,1.91341731733094,20,dna binding
APR_HepG2_P-H2AX_72h_up,"Data from the assay component APR_HepG2_P-H2AX_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_P-H2AX_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is cellular response to DNA damage stimulus.",NP_002096.1,H2AFX,"H2A histone family, member X",https://www.ncbi.nlm.nih.gov/gene/3014,,,Active,1.39710005503446,1.2740056470587027,109.56430013328092,2.03966906892244,0.109661998615151,1.38573246512513,log2_fold_induction,2.30102999566398,1.09661998615151,,2.10994912975535,1.97573904140117,1.92038875522729,20,dna binding
ATG_AP_1_CIS_up,"Data from the assay component ATG_AP_1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_AP_1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene FOS and JUN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.","NP_005243.1|NP_002219.1","FOS | JUN","FBJ murine osteosarcoma viral oncogene homolog , jun proto-oncogene","https://www.ncbi.nlm.nih.gov/gene/2353 , https://www.ncbi.nlm.nih.gov/gene/3725",,,Active,0.8619454284266508,1.4370687557932353,13.498002818958335,1.1302695145045791,0.11995882938125292,0.8429375845932023,log2_fold_induction,1.47712125471966,0.5997941469062646,,1.2182454281991406,1.094876057781004,0.8967174182412739,30,dna binding
ATG_DR4_LXR_CIS_dn,ATG_DR4_LXR_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,"NP_009052.3|NP_005684.2","NR1H2 | NR1H3","nuclear receptor subfamily 1, group H, member 2 , nuclear receptor subfamily 1, group H, member 3","https://www.ncbi.nlm.nih.gov/gene/7376 , https://www.ncbi.nlm.nih.gov/gene/10062",,,Active,1.4389344165480777,2.4326841588582284,47.31094214936383,1.6749615966682168,0.11830014277097414,1.1601685142476117,log2_fold_induction,2,0.5915007138548707,,1.5914258212578487,1.4155352944036184,1.1644706989884135,30,nuclear receptor
ATG_EGR_CIS_up,"Data from the assay component ATG_EGR_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_EGR_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene EGR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.",NP_001955.1,EGR1,early growth response 1,https://www.ncbi.nlm.nih.gov/gene/1958,,,Active,1.5066008797408639,2.159477009162138,54.008963437840215,1.7324658422035029,0.13953386614895374,1.1348572961840437,log2_fold_induction,2,0.6976693307447688,"[""Only highest conc above baseline, active""]",1.6919151183115526,1.4707010742370477,1.130319328481432,30,dna binding
ATG_ERa_TRANS_up,"Data from the assay component ATG_ERa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ERa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2,ESR1,estrogen receptor 1,https://www.ncbi.nlm.nih.gov/gene/2099,"[200,29,165,53,52,167,112,30,67,200,29,165,53,52,30,67,112,167]",[1181],Active,2.5659008866335418,2.3217605319621835,21.387893354256963,1.3301680099255355,0.22103062321117403,2.46081799325702,log2_fold_induction,1.84509804001426,1.10515311605587,,1.2641075274505884,1.0805335472782116,0.809852085054933,20,nuclear receptor
ATG_ERE_CIS_up,"Data from the assay component ATG_ERE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ERE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2,ESR1,estrogen receptor 1,https://www.ncbi.nlm.nih.gov/gene/2099,"[200,29,165,53,52,167,112,30,67,200,29,165,53,52,30,67,112,167]",[1181],Active,0.6032062732298937,1.1937338091954883,11.706239761804897,1.0684174148885741,0.10106210757931403,0.6566360331120955,log2_fold_induction,1.47712125471966,0.5053105378965701,"[""Borderline active""]",1.1575167386535314,1.0689873487158235,0.949137099908258,30,nuclear receptor
ATG_FXR_TRANS_up,"Data from the assay component ATG_FXR_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_FXR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_001193922.1,NR1H4,"nuclear receptor subfamily 1, group H, member 4",https://www.ncbi.nlm.nih.gov/gene/9971,"[27,61,27,61]",[479],Active,2.0570055207214377,2.4832034115661297,125.76997121925817,2.0995769615343534,0.16567354177595192,2.0550458288488356,log2_fold_induction,2.47712125471966,0.8283677088797596,"[""Only one conc above baseline, active""]",2.078176786814973,2.037483466437138,1.9802961726734039,30,nuclear receptor
ATG_HIF1a_CIS_up,"Data from the assay component ATG_HIF1a_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_HIF1a_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HIF1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix protein.",NP_001521.1,HIF1A,"hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)",https://www.ncbi.nlm.nih.gov/gene/3091,"[122,123,220,150,122,123,220,150]",[801],Active,1.4171139422958392,1.8512603599885686,42.61038209047221,1.6295154285689035,0.15309720587379613,1.1411766708175701,log2_fold_induction,2,0.7654860293689807,,1.671869842160765,1.4362091116066396,1.0516233087653184,30,dna binding
ATG_HSE_CIS_up,"Data from the assay component ATG_HSE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_HSE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is heat shock protein.",NP_005517.1,HSF1,heat shock transcription factor 1,https://www.ncbi.nlm.nih.gov/gene/3297,,,Active,2.8962726902396305,6.09798847900057,71.4421252276709,1.8539543652662964,0.09499108436211133,2.286520765194783,log2_fold_induction,2,0.47495542181055667,"[""Only highest conc above baseline, active""]",1.6739339023962172,1.6091290450814106,1.611116568286128,30,dna binding
ATG_ISRE_CIS_dn,ATG_ISRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_002189.1,IRF1,interferon regulatory factor 1,https://www.ncbi.nlm.nih.gov/gene/3659,,,Active,2.039660644416653,2.88485452570398,39.641071727646164,1.5981453874658849,0.14140474857524557,1.771972590522217,log2_fold_induction,2,0.7070237428762278,,1.4632712923783058,1.313624217683712,1.1306083111244751,30,dna binding
ATG_LXRa_TRANS_up,"Data from the assay component ATG_LXRa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_LXRa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_005684.2,NR1H3,"nuclear receptor subfamily 1, group H, member 3",https://www.ncbi.nlm.nih.gov/gene/10062,"[61,58,34,34,61,58]",[483],Active,1.2935196351699507,1.1312438884555496,86.81903263424726,1.9386149424800025,0.2286897897739719,1.2918872412395357,log2_fold_induction,2.30102999566398,1.1434489488698594,"[""Hit-call potentially confounded by overfitting"",""Borderline active""]",2.048894299846688,1.945224457450476,1.8192921671529865,20,nuclear receptor
ATG_MRE_CIS_up,"Data from the assay component ATG_MRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_MRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MTF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.",NP_005946.2,MTF1,metal-regulatory transcription factor 1,https://www.ncbi.nlm.nih.gov/gene/4520,,,Active,2.313545807367976,3.846728593853397,54.07032137377463,1.7329589508673238,0.12028640705584168,1.8344899457176567,log2_fold_induction,2,0.6014320352792084,,1.5155498946679398,1.382070214032229,1.2763445329836067,30,dna binding
ATG_NRF2_ARE_CIS_up,"Data from the assay component ATG_NRF2_ARE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NRF2_ARE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFE2L2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_006155.2,NFE2L2,"nuclear factor, erythroid 2-like 2",https://www.ncbi.nlm.nih.gov/gene/4780,"[61,61]",[478],Active,1.6272434580657087,2.095374216478993,12.124661949475499,1.0836696387774727,0.15531769411576343,1.652192474426741,log2_fold_induction,1.47712125471966,0.7765884705788172,,1.078724324466417,1.0340948085031811,0.9643893237774758,30,dna binding
ATG_NURR1_TRANS_up,"Data from the assay component ATG_NURR1_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NURR1_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR4A2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.",NP_006177.1,NR4A2,"nuclear receptor subfamily 4, group A, member 2",https://www.ncbi.nlm.nih.gov/gene/4929,,,Active,1.5180718965602065,1.7595267314212302,35.515667229206194,1.55041997813071,0.17255457043656366,1.4963319721351318,log2_fold_induction,2.47712125471966,0.8627728521828183,,1.6122198269517716,1.4023937415555923,1.0567521803733277,30,nuclear receptor
ATG_Oct_MLP_CIS_up,"Data from the assay component ATG_Oct_MLP_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Oct_MLP_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene POU2F1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is POU domain protein.",NP_002688.3,POU2F1,POU class 2 homeobox 1,https://www.ncbi.nlm.nih.gov/gene/5451,,,Active,1.4036067285311016,2.071163047482075,50.60106481700138,1.7041596559560483,0.13553802345377633,1.1102865861114695,log2_fold_induction,2,0.6776901172688816,"[""Only highest conc above baseline, active""]",1.6870395596223515,1.4808030618612493,1.1569680587579425,30,dna binding
ATG_p53_CIS_dn,ATG_p53_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_000537.3,TP53,tumor protein p53,https://www.ncbi.nlm.nih.gov/gene/7157,,,Active,0.8565665660829224,1.3400362526207785,34.59515120626151,1.539015233130046,0.12784229746138445,0.8563734076153698,log2_fold_induction,2,0.6392114873069222,"[""Only highest conc above baseline, active""]",1.5975751694077855,1.5276274004845314,1.4197337198102904,30,dna binding
ATG_Pax6_CIS_up,"Data from the assay component ATG_Pax6_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Pax6_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PAX6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is paired box protein.",NP_000271.1,PAX6,paired box 6,https://www.ncbi.nlm.nih.gov/gene/5080,,,Active,1.3133984770955345,2.0692502238368844,54.223693351702444,1.7341890954583354,0.12694438419923712,1.021184372217903,log2_fold_induction,2,0.6347219209961856,"[""Only highest conc above baseline, active""]",1.7190929220716642,1.5322735137747205,1.2388062738798842,30,dna binding
ATG_PPARa_TRANS_up,"Data from the assay component ATG_PPARa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PPARa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_005027.2,PPARA,peroxisome proliferator-activated receptor alpha,https://www.ncbi.nlm.nih.gov/gene/5465,"[51,18,318,6,36,61,58,37,166,37,6,318,51,18,166,36,61,58]",,Active,3.314816511270058,2.8647440470166567,14.339133753308703,1.1565229158003076,0.23142147827985585,3.34994632976326,log2_fold_induction,2.30102999566398,1.1571073913992793,,1.0180511443576439,0.8613483381795224,0.6682514394325969,20,nuclear receptor
ATG_PPARg_TRANS_up,"Data from the assay component ATG_PPARg_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PPARg_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_056953.2,PPARG,peroxisome proliferator-activated receptor gamma,https://www.ncbi.nlm.nih.gov/gene/5468,"[72,36,58,34,163,34,36,58,72,163]",,Active,3.281862000534403,2.860097160237614,43.42173935509434,1.6377072161057313,0.2294930428350727,3.2179677661585653,log2_fold_induction,2.30102999566398,1.1474652141753636,,1.5319492468516671,1.411710982241511,1.2632901118616942,20,nuclear receptor
ATG_PPRE_CIS_up,"Data from the assay component ATG_PPRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PPRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARA and PPARD and PPARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.","NP_005027.2|NP_006229.1|NP_056953.2","PPARA | PPARD | PPARG","peroxisome proliferator-activated receptor alpha , peroxisome proliferator-activated receptor delta , peroxisome proliferator-activated receptor gamma","https://www.ncbi.nlm.nih.gov/gene/5465 , https://www.ncbi.nlm.nih.gov/gene/5467 , https://www.ncbi.nlm.nih.gov/gene/5468",,,Active,3.042499462873044,3.3979786767477647,38.82163847476865,1.5890738609218533,0.1790770191521653,2.3884955375708383,log2_fold_induction,2,0.8953850957608266,,1.2492884774561381,0.9909036367083706,0.7354694000660335,30,nuclear receptor
ATG_PXRE_CIS_up,"Data from the assay component ATG_PXRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PXRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_071285.1,NR1I2,"nuclear receptor subfamily 1, group I, member 2",https://www.ncbi.nlm.nih.gov/gene/8856,"[8,11,60,8,11,60]",,Active,1.7075496051609287,2.5623299489438116,10.19559011903613,1.008412367732995,0.13328100901796647,1.337056517796295,log2_fold_induction,1.47712125471966,0.6664050450898323,,0.9112549535456225,0.7503821629260856,0.5299563882891063,30,nuclear receptor
ATG_PXR_TRANS_up,"Data from the assay component ATG_PXR_TRANS was analyzed into 1 assay endpoint. This assay endpoint, ATG_PXR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_071285.1,NR1I2,"nuclear receptor subfamily 1, group I, member 2",https://www.ncbi.nlm.nih.gov/gene/8856,"[8,11,60,8,11,60]",,Active,1.9888607582886797,1.5440882748614908,47.66042168220163,1.678157880508195,0.2576097222766731,1.9782716997126786,log2_fold_induction,2.30102999566398,1.2880486113833656,,1.750706762581499,1.6241267946765203,1.4162539669017087,20,nuclear receptor
ATG_RARa_TRANS_dn,ATG_RARa_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_000955.1,RARA,"retinoic acid receptor, alpha",https://www.ncbi.nlm.nih.gov/gene/5914,,,Active,1.202298839348234,1.04912386706838,109.2658113321502,2.0384842948639825,0.22920055049512475,1.2019079482801396,log2_fold_induction,2.47712125471966,1.1460027524756238,"[""Borderline active"",""Only one conc above baseline, active""]",2.202072729543886,2.0542074346249666,1.9192039789135178,30,nuclear receptor
ATG_RORE_CIS_up,"Data from the assay component ATG_RORE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RORE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RORA and RORB and RORC. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.","NP_599023.1|NP_008845.2|NP_005051.2","RORA | RORB | RORC","RAR-related orphan receptor A , RAR-related orphan receptor B , RAR-related orphan receptor C","https://www.ncbi.nlm.nih.gov/gene/6095 , https://www.ncbi.nlm.nih.gov/gene/6096 , https://www.ncbi.nlm.nih.gov/gene/6097",,,Active,1.3966233734253062,2.0398339760006428,36.96438426045857,1.5677834762710623,0.13693500450105905,1.1193008392964652,log2_fold_induction,2,0.6846750225052953,,1.5541084404948355,1.2613276616945313,0.7985487651699268,30,nuclear receptor
ATG_RXRb_TRANS_up,"Data from the assay component ATG_RXRb_TRANS was analyzed into 1 assay endpoint. This assay endpoint, ATG_RXRb_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RXRB. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_068811.1,RXRB,"retinoid X receptor, beta",https://www.ncbi.nlm.nih.gov/gene/6257,,,Active,4.927306579044045,4.9600633502287,16.07794595369292,1.2062305644399718,0.19867917932204862,4.106088856723263,log2_fold_induction,1.84509804001426,0.9933958966102431,,0.9133646360561267,0.784184902755952,0.7386646938128953,20,nuclear receptor
ATG_TCF_b_cat_CIS_dn,ATG_TCF_b_cat_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,"NP_003193.2|NP_001139746.1|NP_057353.1|NP_112573.1","TCF7 | TCF7L2 | LEF1 | TCF7L1","transcription factor 7 (T-cell specific, HMG-box) , transcription factor 7-like 2 (T-cell specific, HMG-box) , lymphoid enhancer-binding factor 1 , transcription factor 7-like 1 (T-cell specific, HMG-box)","https://www.ncbi.nlm.nih.gov/gene/6932 , https://www.ncbi.nlm.nih.gov/gene/6934 , https://www.ncbi.nlm.nih.gov/gene/51176 , https://www.ncbi.nlm.nih.gov/gene/83439",,,Active,0.8579016169635888,1.2419032139127448,31.526080902837137,1.4986699857158603,0.13815917494257557,1.6106850396154542,log2_fold_induction,2.47712125471966,0.6907958747128778,,1.6062830035542526,1.493551160514555,1.3320641236229114,30,dna binding
ATG_TGFb_CIS_up,"Data from the assay component ATG_TGFb_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_TGFb_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TGFB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor intended target family, where the subfamily is transforming growth factor beta.",P01137.2,TGFB1,"transforming growth factor, beta 1",https://www.ncbi.nlm.nih.gov/gene/7040,,,Active,1.0050691892783041,1.2951409500464381,26.20324670883209,1.4183551058377566,0.1552061479088074,1.0046815456144627,log2_fold_induction,1.84509804001426,0.776030739544037,"[""Only one conc above baseline, active""]",1.4846018026694006,1.4103648570798377,1.299074106691327,20,growth factor
ATG_VDRE_CIS_up,"Data from the assay component ATG_VDRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_VDRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene VDR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_000367.1,VDR,"vitamin D (1,25- dihydroxyvitamin D3) receptor",https://www.ncbi.nlm.nih.gov/gene/7421,,,Active,1.898807873901653,2.6148060640632944,47.15689822416772,1.6735452313588073,0.1452350826317871,1.4357998644302368,log2_fold_induction,2,0.7261754131589355,,1.5157990665762968,1.274798020616866,0.9502710273563328,30,nuclear receptor
ATG_Xbp1_CIS_up,"Data from the assay component ATG_Xbp1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Xbp1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene XBP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_005071.2,XBP1,X-box binding protein 1,https://www.ncbi.nlm.nih.gov/gene/7494,,,Active,1.054598985504297,1.790447826968905,111.01858540154869,2.0453956892522323,0.11780281666064009,1.0542277279821843,log2_fold_induction,2.47712125471966,0.5890140833032005,"[""Only one conc above baseline, active""]",2.0581654918233316,2.0081892798229775,1.926078432390364,30,dna binding
BSK_3C_HLADR_down,"Data from the assay component BSK_3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_HLADR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""MHC Class II"".",NP_061984.2,HLA-DRA,"major histocompatibility complex, class II, DR alpha",https://www.ncbi.nlm.nih.gov/gene/3122,,,Active,0.36682469950203334,4.632721986736617,60,1.7781512503836436,0.025758990402599997,0.30568725,log10_fold_induction,1.77815125038364,0.07918124604762482,"[""Only one conc above baseline, active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",1.7781512503836436,1.7781512503836436,1.5710884635027778,30,cell adhesion molecules
BSK_3C_MCP1_down,"Data from the assay component BSK_3C_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002973.1,CCL2,chemokine (C-C motif) ligand 2,https://www.ncbi.nlm.nih.gov/gene/6347,,,Active,0.3209029918685816,3.7858709016947434,60,1.7781512503836436,0.028254440453399997,0.26741916,log10_fold_induction,1.77815125038364,0.08476332136019998,"[""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.7781512503836436,1.7781512503836436,1.5710299659714355,30,cytokine
BSK_3C_Proliferation_down,"Data from the assay component BSK_3C_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_3C_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.6844763474906348,5.827647827900155,60,1.7781512503836436,0.0391510930713,0.57039696,log10_fold_induction,1.77815125038364,0.1174532792139,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy""]",1.7781512503836436,1.7781512503836436,1.5710803123033599,30,cell cycle
BSK_3C_SRB_down,"Data from the assay component BSK_3C_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_3C_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.5385087581565271,6.800963422988222,60,1.7781512503836436,0.02172150128694,0.4487573,log10_fold_induction,1.77815125038364,0.07918124604762482,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.7781512503836436,1.7781512503836436,1.5120864225280055,30,cell cycle
BSK_3C_TissueFactor_down,"Data from the assay component BSK_3C_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_TissueFactor_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""coagulation factor"".",NP_001984.1,F3,"coagulation factor III (thromboplastin, tissue factor)",https://www.ncbi.nlm.nih.gov/gene/2152,,,Active,0.3798100199718518,2.917337260583765,60,1.7781512503836436,0.04339688170481999,0.31650835,log10_fold_induction,1.77815125038364,0.13019064511446,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.7781512503836436,1.7781512503836436,1.1880935888526447,30,cytokine
BSK_3C_uPAR_down,"Data from the assay component BSK_3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_uPAR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator"".",NP_002650.1,PLAUR,"plasminogen activator, urokinase receptor",https://www.ncbi.nlm.nih.gov/gene/5329,,,Active,0.2798082566306487,2.3865748009098753,60,1.7781512503836436,0.0390808697223,0.23317355,log10_fold_induction,1.77815125038364,0.1172426091669,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy""]",1.7781512503836436,1.7781512503836436,1.43551342738008,30,cytokine
BSK_3C_VCAM1_down,"Data from the assay component BSK_3C_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_001069.1,VCAM1,vascular cell adhesion molecule 1,https://www.ncbi.nlm.nih.gov/gene/7412,,,Active,0.7644779972810516,9.654786144957155,60,1.7781512503836436,0.0189344513925,0.637065,log10_fold_induction,1.77815125038364,0.07918124604762482,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.7781512503836436,1.7781512503836436,1.3838857975866599,30,cell adhesion molecules
BSK_4H_Eotaxin3_down,"Data from the assay component BSK_4H_Eotaxin3 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_Eotaxin3_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL26. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_006063.1,CCL26,chemokine (C-C motif) ligand 26,https://www.ncbi.nlm.nih.gov/gene/10344,,,Active,0.27208280399663487,3.345395619338692,60,1.7781512503836436,0.027110177186399995,0.22673567,log10_fold_induction,1.77815125038364,0.08133053155919999,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.7781512503836436,1.7781512503836436,1.2246615888551882,30,cytokine
BSK_4H_SRB_down,"Data from the assay component BSK_4H_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_4H_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.1364792469205744,1.7236309572406423,60,1.7781512503836436,0.02048812375239,0.1362326,log10_fold_induction,1.77815125038364,0.07918124604762482,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.7781512503836436,1.7781512503836436,1.315942526019935,30,cell cycle
BSK_BE3C_HLADR_down,"Data from the assay component BSK_BE3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_HLADR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""MHC Class II"".",NP_061984.2,HLA-DRA,"major histocompatibility complex, class II, DR alpha",https://www.ncbi.nlm.nih.gov/gene/3122,,,Active,0.9705331556161336,12.257108899655242,7,0.8450980400142568,0.025097172292079997,0.80877763,log10_fold_induction,1.77815125038364,0.07918124604762482,"[""Hit-call potentially confounded by overfitting""]",0.8450980400142568,0.8450980400142568,1.323024474626388,30,cell adhesion molecules
BSK_BE3C_ICAM1_down,"Data from the assay component BSK_BE3C_ICAM1 was analyzed at the endpoint, BSK_BE3C_ICAM1_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.",NP_000192.2,ICAM1,intercellular adhesion molecule 1,https://www.ncbi.nlm.nih.gov/gene/3383,,,Active,1.1858950061731717,14.976968226288031,60,1.7781512503836436,0.016780337300369996,0.98824584,log10_fold_induction,1.77815125038364,0.07918124604762482,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.7781512503836436,1.7781512503836436,1.5713872458099698,30,cell adhesion molecules
BSK_BE3C_IL1a_down,"Data from the assay component BSK_BE3C_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_IL1a_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000566.3,IL1A,"interleukin 1, alpha",https://www.ncbi.nlm.nih.gov/gene/3552,,,Active,0.40274205065661606,5.045715262218264,39.99999999999999,1.6020599913279623,0.026606208087899996,0.301095355,log10_fold_induction,1.60205999132796,0.07981862426369998,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279623,1.6020599913279623,1.2278239131899582,20,cytokine
BSK_BE3C_IL8_down,"Data from the assay component BSK_BE3C_IL8 was analyzed at the endpoint, BSK_BE3C_IL8_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",NP_000575.1,CXCL8,chemokine (C-X-C motif) ligand 8,https://www.ncbi.nlm.nih.gov/gene/3576,,,Active,0.5543806073123511,4.792104427130183,20.000000000000004,1.3010299956639813,0.038562084483089995,0.4639791,log10_fold_induction,1.77815125038364,0.11568625344926999,"[""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",1.3010299956639813,1.3010299956639813,1.010943091917973,30,cytokine
BSK_BE3C_IP10_down,"Data from the assay component BSK_BE3C_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_IP10_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_001556.2,CXCL10,chemokine (C-X-C motif) ligand 10,https://www.ncbi.nlm.nih.gov/gene/3627,,,Active,1.0168121997417199,12.148340183544633,10,1,0.027899893713299997,0.8310526,log10_fold_induction,1.60205999132796,0.08369968113989999,,1,1,0.9327982086073188,20,cytokine
BSK_BE3C_ITAC_down,"Data from the assay component BSK_BE3C_ITAC was analyzed at the endpoint, BSK_BE3C_ITAC_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",,CXCL11,C-X-C motif chemokine ligand 11,https://www.ncbi.nlm.nih.gov/gene/6373,,,Active,1.2591436798500137,15.902044268066732,60,1.7781512503836436,0.015787450295484,1.0492864,log10_fold_induction,1.77815125038364,0.07918124604762482,"[""Hit-call potentially confounded by overfitting""]",1.7781512503836436,1.7781512503836436,1.3781560747335049,30,cytokine
BSK_BE3C_Keratin818_down,"Data from the assay component BSK_BE3C_Keratin818 was analyzed at the endpoint, BSK_BE3C_Keratin818_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'keratin'.",,KRT18,keratin 18,https://www.ncbi.nlm.nih.gov/gene/3875,,,Active,0.3900028421804865,4.925444617857025,60,1.7781512503836436,0.0193323248937,0.32500237,log10_fold_induction,1.77815125038364,0.07918124604762482,"[""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",1.7781512503836436,1.7781512503836436,1.406071507492385,30,cell adhesion molecules
BSK_BE3C_MIG_down,"Data from the assay component BSK_BE3C_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002407.1,CXCL9,chemokine (C-X-C motif) ligand 9,https://www.ncbi.nlm.nih.gov/gene/4283,,,Active,1.5217137591771936,19.218108265964073,60,1.7781512503836436,0.0077791965661199985,1.2680948,log10_fold_induction,1.77815125038364,0.07918124604762482,"[""Hit-call potentially confounded by overfitting""]",1.7781512503836436,1.7781512503836436,1.468573878355119,30,cytokine
BSK_BE3C_MMP1_down,"Data from the assay component BSK_BE3C_MMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_MMP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",NP_002412.1,MMP1,matrix metallopeptidase 1 (interstitial collagenase),https://www.ncbi.nlm.nih.gov/gene/4312,,,Active,0.7334099270254211,7.9703874897031035,60,1.7781512503836436,0.030672282369078,0.61117494,log10_fold_induction,1.77815125038364,0.092016847107234,"[""Borderline active"",""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Noisy data""]",1.7781512503836436,1.7781512503836436,1.571622407603819,30,protease
BSK_BE3C_MMP9_down,"Data from the assay component BSK_BE3C_MMP9 was analyzed at the endpoint, BSK_BE3C_MMP9_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.",AAM97934.1,MMP9,"matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)",https://www.ncbi.nlm.nih.gov/gene/4318,,,Active,0.7494820074500638,9.46539799334903,60,1.7781512503836436,0.024248268445799998,0.62456834,log10_fold_induction,1.77815125038364,0.07918124604762482,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",1.7781512503836436,1.7781512503836436,1.5715313184657613,30,protease
BSK_BE3C_PAI1_down,"Data from the assay component BSK_BE3C_PAI1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_PAI1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SERPINE1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator inhibitor"".",NP_000593.1,SERPINE1,"serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1",https://www.ncbi.nlm.nih.gov/gene/5054,,,Active,0.7362157199516111,6.581041026382392,20.000000000000004,1.3010299956639813,0.0372897295428,0.6135131,log10_fold_induction,1.77815125038364,0.11186918862840001,"[""Hit-call potentially confounded by overfitting""]",1.3010299956639813,1.3010299956639813,1.2241716395675324,30,cytokine
BSK_BE3C_SRB_down,"Data from the assay component BSK_BE3C_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_BE3C_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.8642187997127284,10.914437986905767,60,1.7781512503836436,0.005817857605706999,0.86135554,log10_fold_induction,1.77815125038364,0.07918124604762482,"[""Hit-call potentially confounded by overfitting""]",1.7781512503836436,1.7781512503836436,1.3490781766496758,30,cell cycle
BSK_BE3C_TGFb1_down,"Data from the assay component BSK_BE3C_TGFb1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_TGFb1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TGFB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""growth factor"" intended target family, where the subfamily is ""transforming growth factor beta"".",P01137.2,TGFB1,"transforming growth factor, beta 1",https://www.ncbi.nlm.nih.gov/gene/7040,,,Active,0.3063569759923974,2.8896102660090146,39.99999999999999,1.6020599913279623,0.0353400571692,0.238691255,log10_fold_induction,1.60205999132796,0.10602017150760001,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279623,1.6020599913279623,0.8968933527968507,20,growth factor
BSK_BE3C_tPA_down,"Data from the assay component BSK_BE3C_tPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_tPA_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAT. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""serine protease"".",NP_000921.1,PLAT,"plasminogen activator, tissue",https://www.ncbi.nlm.nih.gov/gene/5327,,,Active,0.4598281955447889,3.4413406725710893,20.000000000000004,1.3010299956639813,0.04453963724175,0.4326606,log10_fold_induction,1.77815125038364,0.13361891172525,"[""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",1.3010299956639813,1.3010299956639813,1.0235573540421192,30,protease
BSK_BE3C_uPA_down,"Data from the assay component BSK_BE3C_uPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_uPA_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAU. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""serine protease"".",NP_002649.1,PLAU,"plasminogen activator, urokinase",https://www.ncbi.nlm.nih.gov/gene/5328,,,Active,0.4198762058736635,5.1140023361217954,39.99999999999999,1.6020599913279623,0.02736774958092,0.325252575,log10_fold_induction,1.60205999132796,0.08210324874276,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.415749245216707,20,protease
BSK_BE3C_uPAR_down,"Data from the assay component BSK_BE3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_uPAR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator"".",NP_002650.1,PLAUR,"plasminogen activator, urokinase receptor",https://www.ncbi.nlm.nih.gov/gene/5329,,,Active,0.6915877187437806,6.081030701794878,60,1.7781512503836436,0.0379095667965,0.5763231,log10_fold_induction,1.77815125038364,0.11372870038949999,"[""Less than 50% efficacy"",""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",1.7781512503836436,1.7781512503836436,1.5715839481381415,30,cytokine
BSK_BF4T_CD90_down,"Data from the assay component BSK_BF4T_CD90 was analyzed at the endpoint, BSK_BF4T_CD90_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'inflammatory factor'.",,THY1,Thy-1 cell surface antigen,https://www.ncbi.nlm.nih.gov/gene/7070,,,Active,0.10511917197760216,1.327576632405817,60,1.7781512503836436,0.012583142067929999,0.08759931,log10_fold_induction,1.77815125038364,0.07918124604762482,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Borderline active""]",1.7781512503836436,1.7781512503836436,0.8095405752184018,30,cytokine
BSK_BF4T_Eotaxin3_down,"Data from the assay component BSK_BF4T_Eotaxin3 was analyzed at the endpoint, BSK_BF4T_Eotaxin3_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",NP_006063.1,CCL26,chemokine (C-C motif) ligand 26,https://www.ncbi.nlm.nih.gov/gene/10344,,,Active,0.4492017464398698,2.934016031448673,20.000000000000004,1.3010299956639813,0.051033775505999995,0.42687845,log10_fold_induction,1.77815125038364,0.15310132651799999,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy""]",1.3010299956639813,1.3010299956639813,0.7700414837200638,30,cytokine
BSK_BF4T_ICAM1_down,"Data from the assay component BSK_BF4T_ICAM1 was analyzed at the endpoint, BSK_BF4T_ICAM1_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.",NP_000192.2,ICAM1,intercellular adhesion molecule 1,https://www.ncbi.nlm.nih.gov/gene/3383,,,Active,0.33339245992255206,4.210497770166787,60,1.7781512503836436,0.01759177814268,0.27782705,log10_fold_induction,1.77815125038364,0.07918124604762482,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy""]",1.7781512503836436,1.7781512503836436,1.1910612167128962,30,cell adhesion molecules
BSK_BF4T_IL1a_down,"Data from the assay component BSK_BF4T_IL1a was analyzed at the endpoint, BSK_BF4T_IL1a_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",NP_000566.3,IL1A,"interleukin 1, alpha",https://www.ncbi.nlm.nih.gov/gene/3552,,,Active,0.8584330786500847,10.841368651028382,60,1.7781512503836436,0.018225014171489997,0.7153609,log10_fold_induction,1.77815125038364,0.07918124604762482,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",1.7781512503836436,1.7781512503836436,1.3705639775862206,30,cytokine
BSK_BF4T_IL8_down,"Data from the assay component BSK_BF4T_IL8 was analyzed at the endpoint, BSK_BF4T_IL8_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",NP_000575.1,CXCL8,chemokine (C-X-C motif) ligand 8,https://www.ncbi.nlm.nih.gov/gene/3576,,,Active,0.32815107552822514,3.2089001149754828,60,1.7781512503836436,0.03408759634875,0.27345923,log10_fold_induction,1.77815125038364,0.10226278904625,"[""Only one conc above baseline, active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",1.7781512503836436,1.7781512503836436,1.5715949745644453,30,cytokine
BSK_BF4T_Keratin818_down,"Data from the assay component BSK_BF4T_Keratin818 was analyzed at the endpoint, BSK_BF4T_Keratin818_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'keratin'.",,KRT18,keratin 18,https://www.ncbi.nlm.nih.gov/gene/3875,,,Active,0.545718118647492,6.892012261580995,60,1.7781512503836436,0.02395139306658,0.4547651,log10_fold_induction,1.77815125038364,0.07918124604762482,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.7781512503836436,1.7781512503836436,1.5714696327684092,30,cell adhesion molecules
BSK_BF4T_MCP1_down,"Data from the assay component BSK_BF4T_MCP1 was analyzed at the endpoint, BSK_BF4T_MCP1_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",NP_002973.1,CCL2,chemokine (C-C motif) ligand 2,https://www.ncbi.nlm.nih.gov/gene/6347,,,Active,0.7905007799952964,8.156500329506175,20.000000000000004,1.3010299956639813,0.032305553773499994,0.65875065,log10_fold_induction,1.77815125038364,0.09691666132049997,"[""Hit-call potentially confounded by overfitting""]",1.3010299956639813,1.3010299956639813,1.142050631957106,30,cytokine
BSK_BF4T_MMP1_down,"Data from the assay component BSK_BF4T_MMP1 was analyzed at the endpoint, BSK_BF4T_MMP1_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.",NP_002412.1,MMP1,matrix metallopeptidase 1 (interstitial collagenase),https://www.ncbi.nlm.nih.gov/gene/4312,,,Active,0.2523945445023654,3.1875545927953537,60,1.7781512503836436,0.01758861894447,0.210329,log10_fold_induction,1.77815125038364,0.07918124604762482,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.7781512503836436,1.7781512503836436,1.5038625430543748,30,protease
BSK_BF4T_MMP3_down,"Data from the assay component BSK_BF4T_MMP3 was analyzed at the endpoint, BSK_BF4T_MMP3_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.",NP_002413.1,MMP3,"matrix metallopeptidase 3 (stromelysin 1, progelatinase)",https://www.ncbi.nlm.nih.gov/gene/4314,,,Active,0.4643968799298698,5.4071949825753745,60,1.7781512503836436,0.02862832956375,0.3869974,log10_fold_induction,1.77815125038364,0.08588498869125,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy""]",1.7781512503836436,1.7781512503836436,1.566470261208123,30,protease
BSK_BF4T_MMP9_down,"Data from the assay component BSK_BF4T_MMP9 was analyzed at the endpoint, BSK_BF4T_MMP9_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.",AAM97934.1,MMP9,"matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)",https://www.ncbi.nlm.nih.gov/gene/4318,,,Active,0.5135096393579862,5.835668258096846,60,1.7781512503836436,0.02933166729423,0.4279247,log10_fold_induction,1.77815125038364,0.08799500188269,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy""]",1.7781512503836436,1.7781512503836436,1.347067274201947,30,protease
BSK_BF4T_PAI1_down,"Data from the assay component BSK_BF4T_PAI1 was analyzed at the endpoint, BSK_BF4T_PAI1_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'plasmogen activator inhibitor'.",NP_000593.1,SERPINE1,"serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1",https://www.ncbi.nlm.nih.gov/gene/5054,,,Active,0.40283255943534957,5.087474364738584,60,1.7781512503836436,0.0164392200252,0.3356938,log10_fold_induction,1.77815125038364,0.07918124604762482,"[""Only one conc above baseline, active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",1.7781512503836436,1.7781512503836436,1.3471653538735064,30,cytokine
BSK_BF4T_SRB_down,"Data from the assay component BSK_BF4T_SRB  was analyzed at the endpoint, BSK_BF4T_SRB_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of  viability reporter, loss-of-signal activity can be used to understand cellular changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",, , , ,,,Active,0.4099073399046861,5.176823558171096,60,1.7781512503836436,0.008569711473119999,0.34158945,log10_fold_induction,1.77815125038364,0.07918124604762482,"[""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",1.7781512503836436,1.7781512503836436,1.342520511747969,30,cell cycle
BSK_BF4T_tPA_down,"Data from the assay component BSK_BF4T_tPA was analyzed at the endpoint, BSK_BF4T_tPA_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'serine protease'.",NP_000921.1,PLAT,"plasminogen activator, tissue",https://www.ncbi.nlm.nih.gov/gene/5327,,,Active,0.3884926799930051,4.515958769575607,20.000000000000004,1.3010299956639813,0.02867554081098,0.3237439,log10_fold_induction,1.77815125038364,0.08602662243294,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy""]",1.3010299956639813,1.3010299956639813,0.9723440683064823,30,protease
BSK_BF4T_uPA_down,"Data from the assay component BSK_BF4T_uPA was analyzed at the endpoint, BSK_BF4T_uPA_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'serine protease'.",NP_002649.1,PLAU,"plasminogen activator, urokinase",https://www.ncbi.nlm.nih.gov/gene/5328,,,Active,0.4263038372156111,5.383899073262928,60,1.7781512503836436,0.01949875037607,0.3552532,log10_fold_induction,1.77815125038364,0.07918124604762482,"[""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.7781512503836436,1.7781512503836436,1.5715356106428606,30,protease
BSK_BF4T_VCAM1_down,"Data from the assay component BSK_BF4T_VCAM1 was analyzed at the endpoint, BSK_BF4T_VCAM1_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.",NP_001069.1,VCAM1,vascular cell adhesion molecule 1,https://www.ncbi.nlm.nih.gov/gene/7412,,,Active,0.32608226398222734,2.915807718489481,7,0.8450980400142568,0.0372775225557,0.27173522,log10_fold_induction,1.77815125038364,0.11183256766710001,"[""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",0.8450980400142568,0.8450980400142568,-0.1652236842334196,30,cell adhesion molecules
BSK_BT_Bcell_Proliferation_up,"Data from the assay component BSK_BT_Bcell_Proliferation  was analyzed at the endpoint, BSK_BT_Bcell_Proliferation_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of  viability reporter, gain-of-signal activity can be used to understand cellular changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'proliferation'.",, , , ,,,Active,0.1707703679962062,2.156702205639624,60,1.7781512503836436,0.025317587765399996,0.14230864,log10_fold_induction,1.77815125038364,0.07918124604762482,"[""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Borderline active"",""Only one conc above baseline, active""]",1.7781512503836436,1.7781512503836436,1.2565719278084813,30,cell cycle
BSK_BT_PBMCCytotoxicity_up,"Data from the assay component BSK_BT_PBMCCytotoxicity  was analyzed at the endpoint, BSK_BT_PBMCCytotoxicity_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of  viability reporter, gain-of-signal activity can be used to understand cellular changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",, , , ,,,Active,0.1025931756452794,1.2956751853030084,60,1.7781512503836436,0.019653024542969997,0.1025739,log10_fold_induction,1.77815125038364,0.07918124604762482,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy""]",1.7781512503836436,1.7781512503836436,1.159410449595945,30,cell cycle
BSK_BT_xTNFa_up,"Data from the assay component BSK_BT_xTNFa was analyzed at the endpoint, BSK_BT_xTNFa_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of  cytokine quantitation reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'inflammatory factor'.",NP_000585.2,TNF,tumor necrosis factor,https://www.ncbi.nlm.nih.gov/gene/7124,,,Active,0.2790296632524511,1.6303024464131692,60,1.7781512503836436,0.05705069507529,0.23252502,log10_fold_induction,1.77815125038364,0.17115208522587,"[""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Borderline active""]",1.7781512503836436,1.7781512503836436,1.5714113078389813,30,cytokine
BSK_hDFCGF_ICAM1_down,"Data from the assay component BSK_hDFCGF_ICAM1 was analyzed at the endpoint, BSK_hDFCGF_ICAM1_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.",NP_000192.2,ICAM1,intercellular adhesion molecule 1,https://www.ncbi.nlm.nih.gov/gene/3383,,,Active,0.1012106399658933,1.27821479223778,60,1.7781512503836436,0.016727676163799998,0.0843422,log10_fold_induction,1.77815125038364,0.07918124604762482,"[""Borderline active"",""Only one conc above baseline, active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",1.7781512503836436,1.7781512503836436,0.551567794070433,30,cell adhesion molecules
BSK_hDFCGF_IP10_down,"Data from the assay component BSK_hDFCGF_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_IP10_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_001556.2,CXCL10,chemokine (C-X-C motif) ligand 10,https://www.ncbi.nlm.nih.gov/gene/3627,,,Active,0.6144872080507958,7.596956283628621,60,1.7781512503836436,0.0269619913164,0.5227546,log10_fold_induction,1.77815125038364,0.0808859739492,"[""Only one conc above baseline, active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",1.7781512503836436,1.7781512503836436,1.2795070037765466,30,cytokine
BSK_hDFCGF_ITAC_down,"Data from the assay component BSK_hDFCGF_ITAC was analyzed at the endpoint, BSK_hDFCGF_ITAC_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",,CXCL11,C-X-C motif chemokine ligand 11,https://www.ncbi.nlm.nih.gov/gene/6373,,,Active,0.5816896796561504,6.980510367640801,60,1.7781512503836436,0.027776845771079996,0.4847414,log10_fold_induction,1.77815125038364,0.08333053731323999,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy""]",1.7781512503836436,1.7781512503836436,1.5715732846223829,30,cytokine
BSK_hDFCGF_MIG_down,"Data from the assay component BSK_hDFCGF_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002407.1,CXCL9,chemokine (C-X-C motif) ligand 9,https://www.ncbi.nlm.nih.gov/gene/4283,,,Active,0.16857826454994274,2.1290175763153396,20.000000000000004,1.3010299956639813,0.015977820005069997,0.14695868,log10_fold_induction,1.77815125038364,0.07918124604762482,"[""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",1.3010299956639813,1.3010299956639813,0.6965919830385324,30,cytokine
BSK_hDFCGF_Proliferation_down,"Data from the assay component BSK_hDFCGF_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_hDFCGF_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.8870814193042322,6.546553311971521,20.000000000000004,1.3010299956639813,0.0451678604517,0.8868795,log10_fold_induction,1.77815125038364,0.1355035813551,"[""Hit-call potentially confounded by overfitting""]",1.3010299956639813,1.3010299956639813,1.2040839826931198,30,cell cycle
BSK_IMphg_CD40_down,"Data from the assay component BSK_IMphg_CD40 was analyzed at the endpoint, BSK_IMphg_CD40_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'inflammatory factor'.",NP_001241.1,CD40,"CD40 molecule, TNF receptor superfamily member 5",https://www.ncbi.nlm.nih.gov/gene/958,,,Active,0.1786335479193362,2.256008295346782,60,1.7781512503836436,0.02465086951362,0.14886129,log10_fold_induction,1.77815125038364,0.07918124604762482,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy""]",1.7781512503836436,1.7781512503836436,1.0539987565973905,30,cytokine
BSK_IMphg_CD69_down,"Data from the assay component BSK_IMphg_CD69 was analyzed at the endpoint, BSK_IMphg_CD69_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'inflammatory factor'.",NP_001772.1,CD69,CD69 molecule,https://www.ncbi.nlm.nih.gov/gene/969,,,Active,0.38441255325328316,3.2438054651149795,60,1.7781512503836436,0.0395022201945,0.3203438,log10_fold_induction,1.77815125038364,0.11850666058349998,"[""Only one conc above baseline, active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",1.7781512503836436,1.7781512503836436,1.5713415660466539,30,cytokine
BSK_IMphg_ESelectin_down,"Data from the assay component BSK_IMphg_ESelectin was analyzed at the endpoint, BSK_IMphg_ESelectin_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'selectins'.",NP_000441.2,SELE,selectin E,https://www.ncbi.nlm.nih.gov/gene/6401,,,Active,0.1421191317832337,1.6973893400254982,60,1.7781512503836436,0.027909356333669994,0.11843261,log10_fold_induction,1.77815125038364,0.08372806900100999,"[""Less than 50% efficacy"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.7781512503836436,1.7781512503836436,1.5718243419564037,30,cell adhesion molecules
BSK_IMphg_IL10_down,"Data from the assay component BSK_IMphg_IL10 was analyzed at the endpoint, BSK_IMphg_IL10_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",,IL10,interleukin 10,https://www.ncbi.nlm.nih.gov/gene/3586,,,Active,0.3658914777286734,2.0573081828418314,60,1.7781512503836436,0.059283206534999994,0.36578226,log10_fold_induction,1.77815125038364,0.17784961960499998,"[""Less than 50% efficacy"",""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",1.7781512503836436,1.7781512503836436,1.2177155476145574,30,cytokine
BSK_IMphg_IL8_up,"Data from the assay component BSK_IMphg_IL8 was analyzed at the endpoint, BSK_IMphg_IL8_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",NP_000575.1,CXCL8,chemokine (C-X-C motif) ligand 8,https://www.ncbi.nlm.nih.gov/gene/3576,,,Active,0.28343235599747846,2.3648766259985146,20.000000000000004,1.3010299956639813,0.03995026673295,0.23619363,log10_fold_induction,1.77815125038364,0.11985080019885,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy""]",1.3010299956639813,1.3010299956639813,0.4014455757683748,30,cytokine
BSK_IMphg_MCP1_down,"Data from the assay component BSK_IMphg_MCP1 was analyzed at the endpoint, BSK_IMphg_MCP1_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",NP_002973.1,CCL2,chemokine (C-C motif) ligand 2,https://www.ncbi.nlm.nih.gov/gene/6347,,,Active,0.10009203576428993,1.2640876566161638,60,1.7781512503836436,0.022998156137879998,0.08341003,log10_fold_induction,1.77815125038364,0.07918124604762482,"[""Less than 50% efficacy"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.7781512503836436,1.7781512503836436,1.5716440411711277,30,cytokine
BSK_IMphg_SRB_down,"Data from the assay component BSK_IMphg_SRB  was analyzed at the endpoint, BSK_IMphg_SRB_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of  viability reporter, loss-of-signal activity can be used to understand cellular changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",, , , ,,,Active,0.09043480987473757,1.1421241062605167,60,1.7781512503836436,0.010601674447769998,0.09013745,log10_fold_induction,1.77815125038364,0.07918124604762482,"[""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Borderline active"",""Only one conc above baseline, active""]",1.7781512503836436,1.7781512503836436,1.3487052383698441,30,cell cycle
BSK_IMphg_SRB.Mphg_down,"Data from the assay component BSK_IMphg_SRB.Mphg  was analyzed at the endpoint, BSK_IMphg_SRB.Mphg_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of  viability reporter, loss-of-signal activity can be used to understand cellular changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",, , , ,,,Active,0.1477210632497586,1.8656067013760986,20.000000000000004,1.3010299956639813,0.02266232833473,0.14770252,log10_fold_induction,1.77815125038364,0.07918124604762482,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy""]",1.3010299956639813,1.3010299956639813,1.1057355772605568,30,cell cycle
BSK_IMphg_VCAM1_down,"Data from the assay component BSK_IMphg_VCAM1 was analyzed at the endpoint, BSK_IMphg_VCAM1_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.",NP_001069.1,VCAM1,vascular cell adhesion molecule 1,https://www.ncbi.nlm.nih.gov/gene/7412,,,Active,0.1768120798405735,2.2330045139000094,60,1.7781512503836436,0.017737878291,0.1473434,log10_fold_induction,1.77815125038364,0.07918124604762482,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy""]",1.7781512503836436,1.7781512503836436,1.280787051165719,30,cell adhesion molecules
BSK_KF3CT_IL1a_down,"Data from the assay component BSK_KF3CT_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_IL1a_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000566.3,IL1A,"interleukin 1, alpha",https://www.ncbi.nlm.nih.gov/gene/3552,,,Active,0.16777953999181064,1.9544604550659865,2,0.3010299956639812,0.0286148093637,0.16775312,log10_fold_induction,1.77815125038364,0.08584442809109999,"[""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Borderline active""]",0.3010299956639812,0.3010299956639812,1.1930896404035078,30,cytokine
BSK_KF3CT_IP10_down,"Data from the assay component BSK_KF3CT_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_IP10_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_001556.2,CXCL10,chemokine (C-X-C motif) ligand 10,https://www.ncbi.nlm.nih.gov/gene/3627,,,Active,0.5608363559167373,7.0829443070321645,40.000000000000014,1.6020599913279625,0.0138351257877,0.45445864,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,1.0121219003047937,20,cytokine
BSK_KF3CT_MCP1_down,"Data from the assay component BSK_KF3CT_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002973.1,CCL2,chemokine (C-C motif) ligand 2,https://www.ncbi.nlm.nih.gov/gene/6347,,,Active,0.46145183999853673,4.015965879012279,2,0.3010299956639812,0.0383014409568,0.3845432,log10_fold_induction,1.77815125038364,0.1149043228704,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy""]",0.3010299956639812,0.3010299956639812,0.40475675513495124,30,cytokine
BSK_KF3CT_MIG_down,"Data from the assay component BSK_KF3CT_MIG was analyzed at the endpoint, BSK_KF3CT_MIG_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",NP_002407.1,CXCL9,chemokine (C-X-C motif) ligand 9,https://www.ncbi.nlm.nih.gov/gene/4283,,,Active,0.11302272712243888,1.4273926310083522,60,1.7781512503836436,0.012277456782989998,0.094185606,log10_fold_induction,1.77815125038364,0.07918124604762482,"[""Borderline active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.7781512503836436,1.7781512503836436,1.3054718495970632,30,cytokine
BSK_KF3CT_MMP9_down,"Data from the assay component BSK_KF3CT_MMP9 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_MMP9_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",AAM97934.1,MMP9,"matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)",https://www.ncbi.nlm.nih.gov/gene/4318,,,Active,0.49571779197092714,5.922320793302202,7,0.8450980400142568,0.027901099882530003,0.41309816,log10_fold_induction,1.77815125038364,0.08370329964759,"[""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",0.8450980400142568,0.8450980400142568,1.0816338251186064,30,protease
BSK_KF3CT_PAI1_down,"Data from the assay component BSK_KF3CT_PAI1 was analyzed at the endpoint, BSK_KF3CT_PAI1_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'plasmogen activator inhibitor'.",NP_000593.1,SERPINE1,"serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1",https://www.ncbi.nlm.nih.gov/gene/5054,,,Active,0.203762986599006,2.5733743376108213,60,1.7781512503836436,0.02022879047385,0.20359753,log10_fold_induction,1.77815125038364,0.07918124604762482,"[""Hit-call potentially confounded by overfitting"",""Borderline active"",""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.7781512503836436,1.7781512503836436,1.2724078248430473,30,cytokine
BSK_LPS_CD40_down,"Data from the assay component BSK_LPS_CD40 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_CD40_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_001241.1,CD40,"CD40 molecule, TNF receptor superfamily member 5",https://www.ncbi.nlm.nih.gov/gene/958,,,Active,0.5410681195377267,3.9199695695670895,60,1.7781512503836436,0.0460095510042,0.4508901,log10_fold_induction,1.77815125038364,0.13802865301259998,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.7781512503836436,1.7781512503836436,1.3666973490446237,30,cytokine
BSK_LPS_CD69_down,"Data from the assay component BSK_LPS_CD69 was analyzed at the endpoint, BSK_LPS_CD69_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'inflammatory factor'.",NP_001772.1,CD69,CD69 molecule,https://www.ncbi.nlm.nih.gov/gene/969,,,Active,0.28597847981967,2.840144872501868,60,1.7781512503836436,0.0335638371348,0.2383154,log10_fold_induction,1.77815125038364,0.1006915114044,"[""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.7781512503836436,1.7781512503836436,1.2050828676189749,30,cytokine
BSK_LPS_IL1a_down,"Data from the assay component BSK_LPS_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_IL1a_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000566.3,IL1A,"interleukin 1, alpha",https://www.ncbi.nlm.nih.gov/gene/3552,,,Active,0.23261115594658194,1.8848218655898723,60,1.7781512503836436,0.041137602124499996,0.19384263,log10_fold_induction,1.77815125038364,0.1234128063735,"[""Only one conc above baseline, active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",1.7781512503836436,1.7781512503836436,1.3144077901811606,30,cytokine
BSK_LPS_MCP1_down,"Data from the assay component BSK_LPS_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002973.1,CCL2,chemokine (C-C motif) ligand 2,https://www.ncbi.nlm.nih.gov/gene/6347,,,Active,0.42283283995832643,4.715268093744747,60,1.7781512503836436,0.029891042711459998,0.3523607,log10_fold_induction,1.77815125038364,0.08967312813438,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.7781512503836436,1.7781512503836436,1.5715839454030842,30,cytokine
BSK_LPS_PGE2_down,"Data from the assay component BSK_LPS_PGE2 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_PGE2_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PTGER2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",NP_000947.2,PTGER2,"prostaglandin E receptor 2 (subtype EP2), 53kDa",https://www.ncbi.nlm.nih.gov/gene/5732,,,Active,0.31520036399507334,2.235948497652236,20.000000000000004,1.3010299956639813,0.04698980683529999,0.26266697,log10_fold_induction,1.77815125038364,0.14096942050589997,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy""]",1.3010299956639813,1.3010299956639813,0.6280901595283783,30,gpcr
BSK_LPS_SRB_down,"Data from the assay component BSK_LPS_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_LPS_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.19116615562785097,2.4142857705582337,60,1.7781512503836436,0.018219059086199998,0.15930513,log10_fold_induction,1.77815125038364,0.07918124604762482,"[""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.7781512503836436,1.7781512503836436,1.5715572266523632,30,cell cycle
BSK_LPS_VCAM1_down,"Data from the assay component BSK_LPS_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_001069.1,VCAM1,vascular cell adhesion molecule 1,https://www.ncbi.nlm.nih.gov/gene/7412,,,Active,0.2593646270866803,3.275581530135069,60,1.7781512503836436,0.0224178208338,0.21613719,log10_fold_induction,1.77815125038364,0.07918124604762482,"[""Less than 50% efficacy"",""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",1.7781512503836436,1.7781512503836436,1.4347811980368548,30,cell adhesion molecules
BSK_MyoF_ACTA1_down,"Data from the assay component BSK_MyoF_ACTA1 was analyzed at the endpoint, BSK_MyoF_ACTA1_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'actin'.",,ACTA1,"actin, alpha 1, skeletal muscle",https://www.ncbi.nlm.nih.gov/gene/58,,,Active,0.3680018399671056,3.6654060784047116,60,1.7781512503836436,0.033466218303,0.3066682,log10_fold_induction,1.77815125038364,0.10039865490899999,"[""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.7781512503836436,1.7781512503836436,1.0788126412090964,30,cell adhesion molecules
BSK_MyoF_CollagenI_down,"Data from the assay component BSK_MyoF_CollagenI was analyzed at the endpoint, BSK_MyoF_CollagenI_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'collagen'.",,COL1A1,collagen type I alpha 1 chain,https://www.ncbi.nlm.nih.gov/gene/1277,,,Active,0.5377883399855147,5.891820427566356,20.000000000000004,1.3010299956639813,0.03042570326082,0.44815695,log10_fold_induction,1.77815125038364,0.09127710978246,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy""]",1.3010299956639813,1.3010299956639813,1.1195691373593428,30,cell adhesion molecules
BSK_MyoF_CollagenIII_down,"Data from the assay component BSK_MyoF_CollagenIII was analyzed at the endpoint, BSK_MyoF_CollagenIII_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'collagen'.",NP_000081.1,COL3A1,"collagen, type III, alpha 1",https://www.ncbi.nlm.nih.gov/gene/1281,,,Active,0.6912657590184542,7.5758600290868685,60,1.7781512503836436,0.030415282065419998,0.5760548,log10_fold_induction,1.77815125038364,0.09124584619626,"[""Only one conc above baseline, active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",1.7781512503836436,1.7781512503836436,1.345887642600525,30,cell adhesion molecules
BSK_MyoF_CollagenIV_up,"Data from the assay component BSK_MyoF_CollagenIV was analyzed at the endpoint, BSK_MyoF_CollagenIV_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'collagen'.",,COL4A1,collagen type IV alpha 1 chain,https://www.ncbi.nlm.nih.gov/gene/1282,,,Active,0.32755479531105025,2.2923890330417875,20.000000000000004,1.3010299956639813,0.04762932041489999,0.3256228,log10_fold_induction,1.77815125038364,0.1428879612447,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy""]",1.3010299956639813,1.3010299956639813,0.828780267294974,30,cell adhesion molecules
BSK_MyoF_IL8_up,"Data from the assay component BSK_MyoF_IL8 was analyzed at the endpoint, BSK_MyoF_IL8_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",NP_000575.1,CXCL8,chemokine (C-X-C motif) ligand 8,https://www.ncbi.nlm.nih.gov/gene/3576,,,Active,0.19023898799873273,1.210357609599583,60,1.7781512503836436,0.0523919505249,0.15853249,log10_fold_induction,1.77815125038364,0.1571758515747,"[""Borderline active"",""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy""]",1.7781512503836436,1.7781512503836436,0.7786681518763292,30,cytokine
BSK_MyoF_VCAM1_down,"Data from the assay component BSK_MyoF_VCAM1 was analyzed at the endpoint, BSK_MyoF_VCAM1_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.",NP_001069.1,VCAM1,vascular cell adhesion molecule 1,https://www.ncbi.nlm.nih.gov/gene/7412,,,Active,0.30190283996272405,3.3488771306288183,60,1.7781512503836436,0.0300501559365,0.2515857,log10_fold_induction,1.77815125038364,0.0901504678095,"[""Less than 50% efficacy"",""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",1.7781512503836436,1.7781512503836436,1.2756319573047408,30,cell adhesion molecules
BSK_SAg_CD38_down,"Data from the assay component BSK_SAg_CD38 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD38_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD38. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""other cytokine"".",NP_001766.2,CD38,CD38 molecule,https://www.ncbi.nlm.nih.gov/gene/952,,,Active,0.46995917885427013,5.9352334335785235,60,1.7781512503836436,0.0243080164845,0.39163265,log10_fold_induction,1.77815125038364,0.07918124604762482,"[""Only one conc above baseline, active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",1.7781512503836436,1.7781512503836436,1.5708466348134211,30,cytokine
BSK_SAg_CD40_down,"Data from the assay component BSK_SAg_CD40 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD40_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_001241.1,CD40,"CD40 molecule, TNF receptor superfamily member 5",https://www.ncbi.nlm.nih.gov/gene/958,,,Active,0.31339715999025863,3.1434479061575917,60,1.7781512503836436,0.0332328459435,0.2611643,log10_fold_induction,1.77815125038364,0.09969853783049999,"[""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.7781512503836436,1.7781512503836436,1.0888869078201453,30,cytokine
BSK_SAg_CD69_down,"Data from the assay component BSK_SAg_CD69 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD69_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD69. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_001772.1,CD69,CD69 molecule,https://www.ncbi.nlm.nih.gov/gene/969,,,Active,0.3946309192528957,3.727185647986011,60,1.7781512503836436,0.03529302057225,0.3288591,log10_fold_induction,1.77815125038364,0.10587906171674999,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy""]",1.7781512503836436,1.7781512503836436,1.2802687419017427,30,cytokine
BSK_SAg_IL8_down,"Data from the assay component BSK_SAg_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000575.1,CXCL8,chemokine (C-X-C motif) ligand 8,https://www.ncbi.nlm.nih.gov/gene/3576,,,Active,0.29774865568106523,1.9821418263807848,60,1.7781512503836436,0.050071872038999994,0.24812388,log10_fold_induction,1.77815125038364,0.150215616117,"[""Only one conc above baseline, active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",1.7781512503836436,1.7781512503836436,1.5716426328223636,30,cytokine
BSK_SAg_MCP1_down,"Data from the assay component BSK_SAg_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002973.1,CCL2,chemokine (C-C motif) ligand 2,https://www.ncbi.nlm.nih.gov/gene/6347,,,Active,0.786628391855953,8.263315055075681,60,1.7781512503836436,0.031731751991099996,0.65552366,log10_fold_induction,1.77815125038364,0.09519525597329999,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",1.7781512503836436,1.7781512503836436,1.5714518071820491,30,cytokine
BSK_SAg_Proliferation_down,"Data from the assay component BSK_SAg_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_SAg_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.24848197172280584,2.0762240198110504,60,1.7781512503836436,0.0398932500141,0.20706831,log10_fold_induction,1.77815125038364,0.1196797500423,"[""Only one conc above baseline, active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",1.7781512503836436,1.7781512503836436,1.5715423898743124,30,cell cycle
BSK_SAg_SRB_down,"Data from the assay component BSK_SAg_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_SAg_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.31174149480096836,3.937062250996486,60,1.7781512503836436,0.017346765986949,0.25978458,log10_fold_induction,1.77815125038364,0.07918124604762482,"[""Only one conc above baseline, active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",1.7781512503836436,1.7781512503836436,1.5715232271074895,30,cell cycle
CCTE_Deisenroth_AIME_384WELL_CTox_Active_dn,"CCTE_Deisenroth_AIME_384WELL_CTox_Active_dn is a component of the CCTE_Deisenroth_AIME_384WELL assay that measures the effect of retroftting the VM7Luc ERTA assay with the Alginate Immobolization of Metabolic Enzymes (AIME) metabolism method. AIME is optimized to impart phase I hepatic metabolism using phenobarbital/beta-naphthoflavone induced hepatic S9 from male Sprague Dawley rats. Parent chemicals are incubated for 2 hours in the AIME assay prior to transfer to the VM7Luc ERTA assay plate. The AIME metabolism assay is run simultaneously in negative (inactive) and positive (active) modes to evaluate the activity of parent and metabolites, respectively. This endpoint evaluates cytotoxicity in metabolism positive mode. Using a type of flourescent probe in VM7Luc cells, loss-of-signal activity can be used to understand loss of viability. This assay endpoint, CCTE_Deisenroth_AIME_384WELL_CTox_Active_dn, was analyzed in the positive fitting direction in the ERTA assay. ",, , , ,,,Active,0.9255873907053129,2.199033293738789,105.68345428439537,2.024006999838632,0.14030216418894872,0.9106448591670925,log2_fold_induction,2.30102999566398,0.4209064925668462,,2.010281198188805,2.010281198188805,1.857857856252565,30,protease
CCTE_Deisenroth_AIME_384WELL_CTox_Inactive_dn,"CCTE_Deisenroth_AIME_384WELL_CTox_Inactive_dn is a component of the CCTE_Deisenroth_AIME_384WELL assay that measures the effect of retroftting the VM7Luc ERTA assay with the Alginate Immobolization of Metabolic Enzymes (AIME) metabolism method. AIME is optimized to impart phase I hepatic metabolism using phenobarbital/beta-naphthoflavone induced hepatic S9 from male Sprague Dawley rats. Parent chemicals are incubated for 2 hours in the AIME assay prior to transfer to the VM7Luc ERTA assay plate. The AIME metabolism assay is run simultaneously in negative (inactive) and positive (active) modes to evaluate the activity of parent and metabolites, respectively. This endpoint evaluates cytotoxicity in metabolism negative mode. Using a type of flourescent probe in VM7Luc cells, loss-of-signal activity can be used to understand loss of viability. This assay endpoint, CCTE_Deisenroth_AIME_384WELL_CTox_Inactive_dn, was analyzed in the positive fitting direction in the ERTA assay. ",, , , ,,,Active,0.782881200944594,2.1390844092641825,112.17904037218105,2.04991172054737,0.121996307945899,0.763088870391464,log2_fold_induction,2.30102999566398,0.365988923837697,"[""Borderline active"",""Only highest conc above baseline, active""]",2.04284223208664,2.04284223208664,1.93063140685135,30,protease
CCTE_GLTED_hDIO2_dn,"Data from the assay component CCTE_GLTED_hDIO2 was analyzed into 1 assay endpoint. This assay endpoint, CCTE_GLTED_hDIO2_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DIO2. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'deiodinase' intended target family, where the subfamily is 'deiodinase Type 2'.",,DIO2,iodothyronine deiodinase 2,https://www.ncbi.nlm.nih.gov/gene/1734,,,Active,49.751730387755714,2.4875865193877855,63.20267582832366,1.8007354655114218,4.347339401816814,40.066757324762,percent_activity,2.30102999566398,20,"[""Less than 50% efficacy""]",1.5567967178366726,1.165105373847325,0.45116619567976457,30,deiodinase
CCTE_GLTED_hIYD_dn,"Data from the assay component CCTE_GLTED_hIYD was analyzed at the assay endpoint CCTE_GLTED_hIYD_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand iodotyrosine deiodinase activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dehalogenase' intended target family, where the subfamily is 'iodotyrosine deiodinase'.",,IYD,iodotyrosine deiodinase,https://www.ncbi.nlm.nih.gov/gene/389434,,,Active,70.55767731423603,3.5278838657118015,86.38477427584502,1.9364372027718697,6.805901797768499,71.1418593342469,percent_activity,2.30102999566398,20,,1.8860896123685202,1.8876622001183496,1.8171498981854601,30,dehalogenase
CCTE_GLTED_hTBG_dn,"Data from the assay component CCTE_GLTED_hTBG was analyzed at the assay endpoint CCTE_GLTED_hTBG_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand a chemical's ability to displace T4 from thyroxine-binding globulin. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'transporter' intended target family, where  the subfamily is 'hormone carrier protein'.",, , , ,,,Active,50.06195278305711,2.5030976391528554,98.15284572752641,1.9919028955391394,7.082443107978216,40.1392059938377,percent_activity,2.30102999566398,20,"[""Only one conc above baseline, active""]",1.8996903306842525,1.9229684426021496,1.4947304845914582,30,transporter
CCTE_GLTED_hTPO_dn,"Data from the assay component CCTE_GLTED_hTPO was analyzed at the assay endpoint CCTE_GLTED_hTPO_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter (the Amplex UltraRed assay), loss-of-signal activity can be used to understand decreased peroxidase activity in the presence of excess hydrogen peroxidase. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'oxidoreductase' intended target family, where the subfamily is 'peroxidase'.",, , , ,,,Active,36.08315013603482,1.8041575068017408,204.37200794728324,2.3104214118808315,5.464548088548561,32.9815812136091,percent_activity,2.47712125471966,20,"[""Only one conc above baseline, active""]",2.3229744159608656,2.2998708079484715,2.183876388642781,30,oxidoreductase
CCTE_GLTED_hTTR_dn,"Data from the assay component CCTE_GLTED_hTTR was analyzed at the assay endpoint CCTE_GLTED_hTTR_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand a chemical's ability to displace T4 from transthyretin. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'transporter' intended target family, where  the subfamily is 'hormone carrier protein'.",, , , ,,,Active,107.2237556837208,5.36118778418604,0.46428572696164705,-0.33321466717827075,2.991935744486705,98.0721138018863,percent_activity,0.778151250383644,20,,-0.9654240748078391,-1.3604483957676488,-1.2764238237420158,30,transporter
CCTE_GLTED_xIYD_dn,"Data from the assay component CCTE_GLTED_xIYD was analyzed at the assay endpoint CCTE_GLTED_xIYD_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand iodotyrosine deiodinase activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dehalogenase' intended target family, where the subfamily is 'iodotyrosine deiodinase'.",, , , ,,,Active,51.97617044451586,2.598808522225793,96.57016774822108,1.9848429858017085,6.997396428418561,33.6049328341775,percent_activity,2.30102999566398,20,,1.6987588414202859,1.7474936156012886,0.6453022540407012,30,dehalogenase
CCTE_Padilla_ZF_144hpf_TERATOSCORE_up,"Data from the assay component CCTE_Padilla_ZF_144hpf_TERATOSCORE was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Padilla_ZF_144hpf_TERATOSCORE_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defect  as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""malformation"" intended target family, where the subfamily is ""total"".",, , , ,,,Active,72.6705056642578,3.63352528321289,62.67477643676342,1.7970927934886,1.53481347591287,48.82556225,percent_activity,1.90308998699194,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.67813901152697,1.46621471592711,1.52717451623443,20,malformation
CCTE_Shafer_MEA_dev_network_spike_number_up,"Data from the assay component CCTE_Shafer_MEA_dev_network_spike_number was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_network_spike_number_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,81.1618131106635,1.0368244745910675,7.987231270608557,0.90239625962904,26.0930739643514,80.0539083557951,percent_activity,1.47712125471966,78.2792218930542,"[""Only highest conc above baseline, active"",""Borderline active""]",1.2494667859667,1.2494667859667,0.671419277754378,30,neurodevelopment
CCTE_Simmons_AUR_TPO_dn,"Data from the assay component CCTE_Simmons_AUR_TPO was analyzed at the endpoint, CCTE_Simmons_AUR_TPO_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, the Amplex UltraRed assay, loss-of-signal activity can be used to understand decreased peroxidase activity in the presence of excess hydrogen peroxidase. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is peroxidase.",P14650.1,Tpo,thyroid peroxidase,https://www.ncbi.nlm.nih.gov/gene/54314,,,Active,32.4432962961376,1.6221648148068801,41.244604027327505,1.61536713847518,5.55295187687267,24.6788889000999,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",2.30234898138653,1.69342036368728,-1.56544122246546,20,oxidoreductase
CCTE_Simmons_CellTiterGLO_HEK293T,"Data from the assay component CCTE_Simmons_CellTiterGLO_HEK293T was analyzed at the endpoint, CCTE_Simmons_CellTiterGLO_HEK293T_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, measures of ATP content for loss-of-signal activity can be used to understand the viability. This assay was run in parallel with aeid 1508 as a means of indicating the range of chemical cytotoxicity or reactivity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,67.4191272555406,3.3709563627770303,73.74384471906559,1.86772577629623,5.60777764752233,40.9715657508669,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.31721655520328,1.16556980016297,0.466588703611394,20,cell cycle
ERFPL_NR_binding_hPPARG_up,"Data from the assay component ERFPL_NR_binding_hPPARG was analyzed at the assay endpoint, ERFPL_NR_binding_hPPARG_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding receptor, gain-of-signal activity can be used to understand changes in binding receptor as they relate to gene PPARG.To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_056953.2,PPARG,peroxisome proliferator-activated receptor gamma,https://www.ncbi.nlm.nih.gov/gene/5468,,,Active,112.493299045404,2.1223969429136305,20.82687038396645,1.31862401420655,10.60059,99.6,percent_activity,2.47712125471966,53.00295,,1.26218980132462,0.86354361124572,0.244731486755944,30,nuclear receptor
LTEA_HepaRG_ABCB11_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_003733.2,ABCB11,"ATP-binding cassette, sub-family B (MDR/TAP), member 11",https://www.ncbi.nlm.nih.gov/gene/8647,"[27,27]",,Active,5.66397895795827,10.091672704106331,56.50797442870136,1.75210973996107,0.187084246719363,6.05887017572008,log2_fold_induction,2,0.561252740158089,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.63226278271694,1.63226278271694,1.63281301883108,20,transporter
LTEA_HepaRG_ABCB1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000918.2,ABCB1,"ATP-binding cassette, sub-family B (MDR/TAP), member 1",https://www.ncbi.nlm.nih.gov/gene/5243,,,Active,0.669369946595669,1.7643081724902483,43.13343040515219,1.63481399899419,0.126465046759354,0.66856946714411,log2_fold_induction,2,0.379395140278062,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.64940559742938,1.64940559742938,1.51553236627241,20,transporter
LTEA_HepaRG_ABCC2_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000383.1,ABCC2,"ATP-binding cassette, sub-family C (CFTR/MRP), member 2",https://www.ncbi.nlm.nih.gov/gene/1244,,,Active,1.01586717130597,2.3670804262727274,91.74557791876794,1.96258514069786,0.143054873284778,0.67668326533815,log2_fold_induction,2,0.429164619854334,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.94561088112509,1.94561088112509,1.84330481698447,20,transporter
LTEA_HepaRG_ABCG2_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_004818.2,ABCG2,"ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group)",https://www.ncbi.nlm.nih.gov/gene/9429,,,Active,2.07250212438222,3.4390655380729602,51.306286170419995,1.71017057918341,0.200878417062049,1.67413908477072,log2_fold_induction,2,0.602635251186147,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.52561500145289,1.52561500145289,1.25536659323085,20,transporter
LTEA_HepaRG_ACOX1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_009223.2,ACOX1,"acyl-CoA oxidase 1, palmitoyl",https://www.ncbi.nlm.nih.gov/gene/51,,,Active,1.08159156692358,2.6741847027207855,95.25755458876864,1.97889942829634,0.134818855982927,0.644840105179845,log2_fold_induction,2,0.404456567948781,"[""Borderline active"",""Hit-call potentially confounded by overfitting"",""Only highest conc above baseline, active"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Only highest conc above baseline, active""]",1.95092400698064,1.95092400698064,1.85961911401462,20,oxidase
LTEA_HepaRG_ACOX1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_009223.2,ACOX1,"acyl-CoA oxidase 1, palmitoyl",https://www.ncbi.nlm.nih.gov/gene/51,,,Active,0.637446813847054,1.5760575160885462,6.735288207496526,0.828356184208575,0.134818855982927,0.517512142260605,log2_fold_induction,2,0.404456567948781,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.04739592100808,1.04739592100808,-0.0442418393941794,20,oxidase
LTEA_HepaRG_ALPP_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001623.3,ALPP,"alkaline phosphatase, placental",https://www.ncbi.nlm.nih.gov/gene/250,,,Active,5.48058647940493,5.461836718642875,74.74600265757735,1.87358797197739,0.33447762243899,3.80764262407214,log2_fold_induction,2,1.00343286731697,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.60620599311847,1.60620599311847,1.48075982837194,20,phosphatase
LTEA_HepaRG_APOA5_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_443200.2,APOA5,apolipoprotein A-V,https://www.ncbi.nlm.nih.gov/gene/116519,,,Active,7.52806184661472,8.801433302738223,81.7941914054493,1.91272246344967,0.285107420866427,6.27348682739423,log2_fold_induction,2,0.855322262599281,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.80120066325453,1.80120066325453,1.79344214954854,20,apolipoprotein
LTEA_HepaRG_APOA5_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_443200.2,APOA5,apolipoprotein A-V,https://www.ncbi.nlm.nih.gov/gene/116519,,,Active,1.08123223763854,1.2641226411583513,2.424747936317277,0.384666598379006,0.285107420866427,0.867873064083196,log2_fold_induction,2,0.855322262599281,"[""Noisy data"",""Borderline active"",""Noisy data"",""Borderline active""]",1.79681234001652,1.79681234001652,-1.94591558903769,20,apolipoprotein
LTEA_HepaRG_BAX_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_620116.1,BAX,BCL2-associated X protein,https://www.ncbi.nlm.nih.gov/gene/581,,,Active,1.35784728105079,2.697921998221226,50.851534932263554,1.70630406645348,0.167764583501183,1.35178713861144,log2_fold_induction,2,0.503293750503549,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.67755538579456,1.67755538579456,1.58698654983607,20,cell cycle
LTEA_HepaRG_BCL2L11_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_619527.1,BCL2L11,BCL2-like 11 (apoptosis facilitator),https://www.ncbi.nlm.nih.gov/gene/10018,,,Active,1.30730156252802,3.1816019221347864,100.27497145877098,2.00119254704062,0.136964710914227,0.823936469701972,log2_fold_induction,2,0.410894132742681,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.66366216403562,1.66366216403562,1.0504572297341,20,cell cycle
LTEA_HepaRG_BCL2_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000624.2,BCL2,B-cell CLL/lymphoma 2,https://www.ncbi.nlm.nih.gov/gene/596,,,Active,2.77050153661801,5.833594024028536,41.83711290725232,1.62156170712808,0.15830729879421,2.76790019890815,log2_fold_induction,2,0.47492189638263,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.5360273209693,1.5360273209693,1.50228053610609,20,cell cycle
LTEA_HepaRG_BID_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_001187.1,BID,BH3 interacting domain death agonist,https://www.ncbi.nlm.nih.gov/gene/637,,,Active,0.877506749365308,1.2572737519782127,33.752845876253204,1.5283103963151,0.232648020630518,0.877351582994027,log2_fold_induction,2,0.697944061891554,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.60201122452836,1.60201122452836,1.40902965661114,20,cell cycle
LTEA_HepaRG_CAT_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001743.1,CAT,catalase,https://www.ncbi.nlm.nih.gov/gene/847,,,Active,2.53233631871201,4.461946722629717,87.25017589267297,1.94076631115145,0.189180229776443,1.89613526518488,log2_fold_induction,2,0.567540689329329,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.87335126352161,1.87335126352161,1.8214859972525,20,catalase
LTEA_HepaRG_CCND1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_444284.1,CCND1,cyclin D1,https://www.ncbi.nlm.nih.gov/gene/595,,,Active,1.95180488196118,4.9779706254825316,56.53271372551806,1.75229983328836,0.130696156379454,1.5627886928098,log2_fold_induction,2,0.392088469138362,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.49922219297287,1.49922219297287,1.34957694104709,20,cell cycle
LTEA_HepaRG_CDKN1A_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000380.1,CDKN1A,"cyclin-dependent kinase inhibitor 1A (p21, Cip1)",https://www.ncbi.nlm.nih.gov/gene/1026,,,Active,2.46999461289764,6.34365423712053,89.12132550525253,1.94998163715793,0.129788211471984,1.76710102570798,log2_fold_induction,2,0.389364634415952,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.85900184330918,1.85900184330918,1.8307013232193,20,cell cycle
LTEA_HepaRG_CYP1A1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000490.1,CYP1A1,"cytochrome P450, family 1, subfamily A, polypeptide 1",https://www.ncbi.nlm.nih.gov/gene/1543,"[57,57]",,Active,1.71678093578942,1.9063043957417192,81.48398426374598,1.91107225623209,0.300193564683644,1.00150519853336,log2_fold_induction,2,0.900580694050932,"[""Borderline active"",""Only highest conc above baseline, active"",""Borderline active"",""Only highest conc above baseline, active""]",1.9379176494932,1.9379176494932,1.3115060146412,20,cyp
LTEA_HepaRG_CYP1A2_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000752.2,CYP1A2,"cytochrome P450, family 1, subfamily A, polypeptide 2",https://www.ncbi.nlm.nih.gov/gene/1544,"[131,131]",,Active,6.27130912086658,6.604904245829207,43.76399699094592,1.64111697950089,0.316497604782422,6.2628925510795,log2_fold_induction,2,0.949492814347266,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.54753154878202,1.54753154878202,1.52181830163376,20,cyp
LTEA_HepaRG_CYP2B6_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000758.1,CYP2B6,"cytochrome P450, family 2, subfamily B, polypeptide 6",https://www.ncbi.nlm.nih.gov/gene/1555,,,Active,5.9232907186207,7.857322962389907,85.69073445472739,1.93293386518192,0.251285361310856,4.59004998459554,log2_fold_induction,2,0.753856083932568,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.82841453743199,1.82841453743199,1.81365354894965,20,cyp
LTEA_HepaRG_CYP2C19_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000760.1,CYP2C19,"cytochrome P450, family 2, subfamily C, polypeptide 19",https://www.ncbi.nlm.nih.gov/gene/1557,,,Active,4.67966757020415,8.344455378595626,91.55455275342256,1.96167994543211,0.186937207917646,3.13539567162961,log2_fold_induction,2,0.560811623752938,"[""Only highest conc above baseline, active"",""Noisy data"",""Only highest conc above baseline, active"",""Noisy data""]",1.85341630405342,1.85341630405342,1.84237903435626,20,cyp
LTEA_HepaRG_CYP2C19_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000760.1,CYP2C19,"cytochrome P450, family 2, subfamily C, polypeptide 19",https://www.ncbi.nlm.nih.gov/gene/1557,,,Active,1.11916063024378,1.995608833416083,3.942337532568911,0.595753804686372,0.186937207917646,0.92495427831144,log2_fold_induction,2,0.560811623752938,"[""Noisy data"",""Noisy data""]",0.598998693644161,0.598998693644161,-1.02433602602526,20,cyp
LTEA_HepaRG_CYP2C8_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000761.3,CYP2C8,"cytochrome P450, family 2, subfamily C, polypeptide 8",https://www.ncbi.nlm.nih.gov/gene/1558,,,Active,10.0308053672304,15.494009591032722,87.63278586735704,1.94266661823879,0.215799646271804,7.44944089670273,log2_fold_induction,2,0.647398938815412,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.79751796703348,1.79751796703348,1.82338623621988,20,cyp
LTEA_HepaRG_CYP2C9_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000762.2,CYP2C9,"cytochrome P450, family 2, subfamily C, polypeptide 9",https://www.ncbi.nlm.nih.gov/gene/1559,,,Active,6.63842087762418,7.049434253138259,93.71186880025148,1.97179459865752,0.313898517206961,4.740556445124,log2_fold_induction,2,0.941695551620883,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.8740802515675,1.8740802515675,1.85251428258819,20,cyp
LTEA_HepaRG_CYP2E1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000764.1,CYP2E1,"cytochrome P450, family 2, subfamily E, polypeptide 1",https://www.ncbi.nlm.nih.gov/gene/1571,,,Active,9.63371089650693,20.115176667181675,82.81239854311582,1.91809536354515,0.159642493756543,7.88927353380578,log2_fold_induction,2,0.478927481269629,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.75792307301661,1.75792307301661,1.79881504912073,20,cyp
LTEA_HepaRG_CYP3A4_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_059488.2,CYP3A4,"cytochrome P450, family 3, subfamily A, polypeptide 4",https://www.ncbi.nlm.nih.gov/gene/1576,,,Active,8.72504854659484,7.353100238078556,86.49280038925272,1.93697995854747,0.395526977922934,6.6469458004068,log2_fold_induction,2,1.1865809337688,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.83660674114648,1.83660674114648,1.81769964017379,20,cyp
LTEA_HepaRG_CYP3A7_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000756.3,CYP3A7,"cytochrome P450, family 3, subfamily A, polypeptide 7",https://www.ncbi.nlm.nih.gov/gene/1551,,,Active,3.35023965105965,4.316832733274864,93.19436388111289,1.9693896483052,0.258695812266514,2.13585071155505,log2_fold_induction,2,0.776087436799542,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.90429915317229,1.90429915317229,1.85010924521793,20,cyp
LTEA_HepaRG_CYP3A7_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000756.3,CYP3A7,"cytochrome P450, family 3, subfamily A, polypeptide 7",https://www.ncbi.nlm.nih.gov/gene/1551,,,Active,1.67446082800908,2.157567238704808,9.857128711563343,0.993750427484437,0.258695812266514,1.35766944405465,log2_fold_induction,2,0.776087436799542,"[""Noisy data"",""Hit-call potentially confounded by overfitting"",""Hit-call potentially confounded by overfitting"",""Noisy data""]",0.942980597622653,0.942980597622653,0.231364804003085,20,cyp
LTEA_HepaRG_CYP4A11_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000769.2,CYP4A11,"cytochrome P450, family 4, subfamily A, polypeptide 11",https://www.ncbi.nlm.nih.gov/gene/1579,,,Active,6.79805149057105,10.634976962871644,87.70400810280508,1.94301944122414,0.213072127136213,5.03668814912675,log2_fold_induction,2,0.639216381408639,"[""Only highest conc above baseline, active"",""Noisy data"",""Only highest conc above baseline, active"",""Noisy data""]",1.82003810574122,1.82003810574122,1.82373912714848,20,cyp
LTEA_HepaRG_CYP4A11_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000769.2,CYP4A11,"cytochrome P450, family 4, subfamily A, polypeptide 11",https://www.ncbi.nlm.nih.gov/gene/1579,,,Active,3.17086387131693,4.960548514619272,2.914192766167221,0.464518275818948,0.213072127136213,2.63957693248057,log2_fold_induction,2,0.639216381408639,"[""Noisy data"",""Noisy data""]",-1.09384517001823,-1.09384517001823,-2.02321634032864,20,cyp
LTEA_HepaRG_CYP4A22_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001010969.2,CYP4A22,"cytochrome P450, family 4, subfamily A, polypeptide 22",https://www.ncbi.nlm.nih.gov/gene/284541,,,Active,5.71085946626036,7.070160474634691,83.13395345751564,1.91977843398388,0.269247045935707,4.65203653831056,log2_fold_induction,2,0.807741137807121,"[""Noisy data"",""Only highest conc above baseline, active"",""Noisy data"",""Only highest conc above baseline, active""]",1.82187841170844,1.82187841170844,1.80049811943731,20,cyp
LTEA_HepaRG_CYP4A22_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_001010969.2,CYP4A22,"cytochrome P450, family 4, subfamily A, polypeptide 22",https://www.ncbi.nlm.nih.gov/gene/284541,,,Active,3.45871297672526,4.2819571949932795,7.146063591468066,0.854066876588055,0.269247045935707,2.74641891354384,log2_fold_induction,2,0.807741137807121,"[""Hit-call potentially confounded by overfitting"",""Noisy data"",""Noisy data"",""Hit-call potentially confounded by overfitting""]",-0.142029726043504,-0.142029726043504,-0.987547364234314,20,cyp
LTEA_HepaRG_CYP7A1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000771.2,CYP7A1,"cytochrome P450, family 7, subfamily A, polypeptide 1",https://www.ncbi.nlm.nih.gov/gene/1581,,,Active,16.6932894487126,31.07916499514933,73.06546917666476,1.86371217737969,0.179040518530855,12.4580940842286,log2_fold_induction,2,0.537121555592565,"[""Noisy data"",""Only highest conc above baseline, active"",""Noisy data"",""Only highest conc above baseline, active""]",1.56655435405374,1.56655435405374,1.67189238986926,20,cyp
LTEA_HepaRG_DDIT3_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_001181982.1,DDIT3,DNA-damage-inducible transcript 3,https://www.ncbi.nlm.nih.gov/gene/1649,,,Active,5.13587062690528,8.934841265544575,62.99167055982259,1.79928312613511,0.191604621140491,4.27189523118576,log2_fold_induction,2,0.574813863421473,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.53897627968786,1.53897627968786,1.52314605219977,20,dna binding
LTEA_HepaRG_EGR1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_001955.1,EGR1,early growth response 1,https://www.ncbi.nlm.nih.gov/gene/1958,,,Active,1.46738693260414,2.779162214003418,85.36544188885944,1.93128209276799,0.175998714673843,1.14481810363276,log2_fold_induction,2,0.527996144021529,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.90000514946526,1.90000514946526,1.81200177908585,20,dna binding
LTEA_HepaRG_EZR_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_003370.2,EZR,ezrin,https://www.ncbi.nlm.nih.gov/gene/7430,,,Active,1.36179086063706,2.8831179053285365,71.43099065178431,1.85388667324676,0.15744423287028,1.00266643203902,log2_fold_induction,2,0.47233269861084,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.76374211092802,1.76374211092802,1.54094811206771,20,membrane protein
LTEA_HepaRG_FABP1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001434.1,FABP1,"fatty acid binding protein 1, liver",https://www.ncbi.nlm.nih.gov/gene/2168,,,Active,10.8537541805753,22.4904423136579,84.34655043048767,1.92606732569647,0.160864691309103,8.64169955383781,log2_fold_induction,2,0.482594073927309,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.75953665557429,1.75953665557429,1.80678701140791,20,transporter
LTEA_HepaRG_FABP1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_001434.1,FABP1,"fatty acid binding protein 1, liver",https://www.ncbi.nlm.nih.gov/gene/2168,,,Active,1.03130937614191,2.1370121015975254,7.5101198377161165,0.875646867023289,0.160864691309103,1.01114565521905,log2_fold_induction,2,0.482594073927309,"[""Noisy data"",""Noisy data""]",0.85314535696366,0.85314535696366,0.49060492482832,20,transporter
LTEA_HepaRG_FASN_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_004095.4,FASN,fatty acid synthase,https://www.ncbi.nlm.nih.gov/gene/2194,"[58,34,34,58]",,Active,4.72810705110592,12.864348171758264,84.52965331598409,1.92700908779425,0.122511895873739,3.74954017009654,log2_fold_induction,2,0.367535687621217,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.79251785255787,1.79251785255787,1.80754156665094,20,lyase
LTEA_HepaRG_FAS_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000034.1,FAS,Fas cell surface death receptor,https://www.ncbi.nlm.nih.gov/gene/355,,,Active,1.44714601192466,2.5942245995989714,38.06034765075602,1.58047275090096,0.185944580145241,1.44650979517337,log2_fold_induction,2,0.557833740435723,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.55515400565657,1.55515400565657,1.46119216883158,20,cytokine receptor
LTEA_HepaRG_FMO3_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001002294.1,FMO3,flavin containing monooxygenase 3,https://www.ncbi.nlm.nih.gov/gene/2328,,,Active,5.63905448910167,12.93389398933146,85.41302190107304,1.93152408741801,0.145330155887393,4.39543965398208,log2_fold_induction,2,0.435990467662179,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.79692631539056,1.79692631539056,1.81224377367152,20,oxidoreductase
LTEA_HepaRG_FOXO3_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_001446.1,FOXO3,forkhead box O3,https://www.ncbi.nlm.nih.gov/gene/2309,,,Active,0.980846334275129,2.556835341735619,64.42849664529219,1.80907799777082,0.127872441668368,0.691177548994785,log2_fold_induction,2,0.383617325005104,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.69004830754986,1.69004830754986,1.21824567512371,20,dna binding
LTEA_HepaRG_GADD45A_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_001915.1,GADD45A,"growth arrest and DNA-damage-inducible, alpha",https://www.ncbi.nlm.nih.gov/gene/1647,,,Active,3.58247706010448,5.915718171735745,44.429500141727786,1.64767142719742,0.201862053831487,3.57704313701603,log2_fold_induction,2,0.605586161494461,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.56122244934857,1.56122244934857,1.52839027756317,20,cell cycle
LTEA_HepaRG_GADD45B_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_056490.2,GADD45B,"growth arrest and DNA-damage-inducible, beta",https://www.ncbi.nlm.nih.gov/gene/4616,,,Active,1.08379033214104,2.58333780971446,47.56446332460593,1.67728260091506,0.139843671504558,0.841066792818065,log2_fold_induction,2,0.419531014513674,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.27462905557875,1.27462905557875,-0.247967846912505,20,mutagenicity response
LTEA_HepaRG_GADD45G_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_006696.1,GADD45G,"growth arrest and DNA-damage-inducible, gamma",https://www.ncbi.nlm.nih.gov/gene/10912,,,Active,3.92543793300227,8.390792916012172,75.09056199752328,1.87558535471422,0.155942271975725,3.06324727944377,log2_fold_induction,2,0.467826815927175,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.66550066898898,1.66550066898898,1.64481085620503,20,mutagenicity response
LTEA_HepaRG_GCLC_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_001489.1,GCLC,"glutamate-cysteine ligase, catalytic subunit",https://www.ncbi.nlm.nih.gov/gene/2729,,,Active,0.920346905021342,2.0982881164240146,46.098319137118835,1.66368509018829,0.146205994911991,0.918131986338772,log2_fold_induction,2,0.438617984735973,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.65845151879247,1.65845151879247,1.54102909736409,20,ligase
LTEA_HepaRG_GSTA2_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000837.3,GSTA2,glutathione S-transferase alpha 2,https://www.ncbi.nlm.nih.gov/gene/2939,,,Active,8.77451194264226,13.338238967923855,63.42626505286952,1.80226913809324,0.219282119719688,9.30448271885247,log2_fold_induction,2,0.657846359159064,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.66582261334116,1.66582261334116,1.68295395361011,20,transferase
LTEA_HepaRG_HGF_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000592.3,HGF,hepatocyte growth factor (hepapoietin A; scatter factor),https://www.ncbi.nlm.nih.gov/gene/3082,,,Active,2.22313152581937,3.131374696345242,62.76353973640261,1.79770742893396,0.236651283797079,1.58881970639801,log2_fold_induction,2,0.709953851391237,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.62018981798207,1.62018981798207,1.28229651560503,20,growth factor
LTEA_HepaRG_HMGCS2_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_005509.1,HMGCS2,3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial),https://www.ncbi.nlm.nih.gov/gene/3158,"[60,60]",,Active,14.2953400414727,27.306609549926993,84.68679785518415,1.92781571180016,0.174504027621778,11.3069034129269,log2_fold_induction,2,0.523512082865334,"[""Noisy data"",""Only highest conc above baseline, active"",""Noisy data"",""Only highest conc above baseline, active""]",1.7503076016279,1.7503076016279,1.80853539791412,20,lyase
LTEA_HepaRG_HMGCS2_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_005509.1,HMGCS2,3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial),https://www.ncbi.nlm.nih.gov/gene/3158,"[60,60]",,Active,1.19861724327687,2.2895693958322583,6.016547001699683,0.779347313790437,0.174504027621778,1.08770854317966,log2_fold_induction,2,0.523512082865334,"[""Noisy data"",""Noisy data""]",0.698474346550385,0.698474346550385,0.0806047691690905,20,lyase
LTEA_HepaRG_HSPA1A_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_005337.2,HSPA1A,heat shock 70kDa protein 1A,https://www.ncbi.nlm.nih.gov/gene/3303,,,Active,3.79759279350474,8.01084413236484,63.656866342398835,1.80384525565317,0.158018835916096,3.01928686229909,log2_fold_induction,2,0.474056507748288,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.51966816284827,1.51966816284827,1.48322172657975,20,dna binding
LTEA_HepaRG_ICAM1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000192.2,ICAM1,intercellular adhesion molecule 1,https://www.ncbi.nlm.nih.gov/gene/3383,,,Active,2.1638960295178,3.781573260090892,85.12230998845278,1.93004340068436,0.190740368332464,1.69649909356884,log2_fold_induction,2,0.572221104997392,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.87450706486985,1.87450706486985,1.81076303766047,20,cell adhesion molecules
LTEA_HepaRG_IGF1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,,IGF1,insulin-like growth factor 1 (somatomedin C),https://www.ncbi.nlm.nih.gov/gene/3479,,,Active,5.37075346231061,11.033209237114852,84.72332693179739,1.92800300139301,0.162260237763032,4.24482323585448,log2_fold_induction,2,0.486780713289096,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.80282301754594,1.80282301754594,1.8087226875391,20,growth factor
LTEA_HepaRG_IGFBP1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000587.1,IGFBP1,insulin-like growth factor binding protein 1,https://www.ncbi.nlm.nih.gov/gene/3484,,,Active,9.23554567982446,10.66571371438319,72.29354981540943,1.85909955034378,0.288636589078576,7.51619677102568,log2_fold_induction,2,0.865909767235728,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.64238768720479,1.64238768720479,1.64920455355279,20,transporter
LTEA_HepaRG_IL6_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000591.1,IL6,interleukin 6,https://www.ncbi.nlm.nih.gov/gene/3569,,,Active,3.69425965694949,4.613324064786358,85.79663220102388,1.93347024070165,0.266926812067961,2.8557734705677,log2_fold_induction,2,0.800780436203883,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.86372966028958,1.86372966028958,1.81418613639158,20,cytokine
LTEA_HepaRG_JUN_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_002219.1,JUN,jun proto-oncogene,https://www.ncbi.nlm.nih.gov/gene/3725,,,Active,2.28776693890246,2.641722941688575,60.9818771037106,1.78520078839992,0.288671066749608,1.79758829633687,log2_fold_induction,2,0.866013200248824,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.70281789752182,1.70281789752182,1.42006699814023,20,dna binding
LTEA_HepaRG_KCNK1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_002236.1,KCNK1,"potassium channel, subfamily K, member 1",https://www.ncbi.nlm.nih.gov/gene/3775,,,Active,2.81138135252601,3.9596840870634806,62.8808422522497,1.79851835019189,0.236667142353684,2.31040181761312,log2_fold_induction,2,0.710001427061052,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.65514014091699,1.65514014091699,1.50818640305839,20,ion channel
LTEA_HepaRG_KRT19_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_002267.2,KRT19,keratin 19,https://www.ncbi.nlm.nih.gov/gene/3880,,,Active,1.07605429411257,1.9864862455764862,36.720475271357756,1.56490829361832,0.180562420456175,1.07569313779925,log2_fold_induction,2,0.541687261368525,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.56564691512964,1.56564691512964,1.44562785032368,20,filaments
LTEA_HepaRG_LDH_cytotoxicity,LDH leakage activity as a measure of membrane integrity and cytotoxicity in the cells.,, , , ,,,Active,36.8695058140418,3.866445338963995,87.43793926557493,1.94169991362445,0.9535762847205,27.51177774,percent_activity,2,9.535762847205,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.88453194710365,1.8073106040578,1.82241958229861,20,cell cycle
LTEA_HepaRG_LIPC_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000227.2,LIPC,"lipase, hepatic",https://www.ncbi.nlm.nih.gov/gene/3990,,,Active,6.92344001174383,13.318016780176391,86.0791944038617,1.93489819387535,0.173285060031091,5.42216902266283,log2_fold_induction,2,0.519855180093273,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.79858059457962,1.79858059457962,1.81561787986784,20,esterase
LTEA_HepaRG_LPL_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000228.1,LPL,lipoprotein lipase,https://www.ncbi.nlm.nih.gov/gene/4023,,,Active,1.76833070031958,4.4837115158457586,65.84400825439684,1.81851626068813,0.131463312189033,1.44155337615498,log2_fold_induction,2,0.394389936567099,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.66573947690486,1.66573947690486,1.54955914663857,20,esterase
LTEA_HepaRG_MIR122_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,,MIR122,microRNA 122,https://www.ncbi.nlm.nih.gov/gene/406906,,,Active,9.29429575957499,8.652231127592357,44.42010355132599,1.64757956663292,0.358069328111801,9.28026865378573,log2_fold_induction,2,1.0742079843354,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.53710604844404,1.53710604844404,1.52829924397114,20,microrna
LTEA_HepaRG_MMP10_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_002416.1,MMP10,matrix metallopeptidase 10 (stromelysin 2),https://www.ncbi.nlm.nih.gov/gene/4319,,,Active,9.92193820400337,4.49847374640135,81.36229399977775,1.91042318496631,0.735207744029526,8.32335142769433,log2_fold_induction,2,2.20562323208858,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.84243290801696,1.84243290801696,1.79113330997369,20,protease
LTEA_HepaRG_MYC_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_002458.2,MYC,v-myc avian myelocytomatosis viral oncogene homolog,https://www.ncbi.nlm.nih.gov/gene/4609,,,Active,3.53484354316442,7.522920293878865,82.92265516461451,1.91867319965529,0.15662550379718,2.88917574637239,log2_fold_induction,2,0.46987651139154,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.81686794062515,1.81686794062515,1.79939288590203,20,dna binding
LTEA_HepaRG_NFE2L2_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_006155.2,NFE2L2,"nuclear factor, erythroid 2-like 2",https://www.ncbi.nlm.nih.gov/gene/4780,"[61,61]",[478],Active,1.22684647928932,3.9921840546905734,44.118614015675725,1.64462186064035,0.102437367823581,1.2250787582503,log2_fold_induction,2,0.307312103470743,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.58508390035275,1.58508390035275,1.52526251478367,20,dna binding
LTEA_HepaRG_NFKB1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_068810.3,NFKB1,nuclear factor of kappa light polypeptide gene enhancer in B-cells 1,https://www.ncbi.nlm.nih.gov/gene/4790,,,Active,0.903369250936707,2.5598468500352323,90.76016415435868,1.95789527270505,0.117633241864225,0.618849668065966,log2_fold_induction,2,0.352899725592675,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.9337575568526,1.9337575568526,1.83860274782148,20,dna binding
LTEA_HepaRG_NQO1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000894.1,NQO1,"NAD(P)H dehydrogenase, quinone 1",https://www.ncbi.nlm.nih.gov/gene/1728,,,Active,1.5479239247809,1.9681201306151213,95.69120182032609,1.98087200907741,0.262166233436355,0.909144210308718,log2_fold_induction,2,0.786498700309065,"[""Only highest conc above baseline, active"",""Borderline active"",""Only highest conc above baseline, active"",""Borderline active""]",1.98263156266728,1.98263156266728,1.8615435497221,20,oxidoreductase
LTEA_HepaRG_PDK4_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_002603.1,PDK4,"pyruvate dehydrogenase kinase, isozyme 4",https://www.ncbi.nlm.nih.gov/gene/5166,,,Active,5.83453193488531,12.087618847911099,32.969042267573805,1.51810633131212,0.160895541360588,4.77999065623526,log2_fold_induction,2,0.482686624081764,,0.619850304499783,0.619850304499783,0.697736236779317,20,kinase
LTEA_HepaRG_SLC22A1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_003048.1,SLC22A1,"solute carrier family 22 (organic cation transporter), member 1",https://www.ncbi.nlm.nih.gov/gene/6580,,,Active,7.24309054222705,13.011161143375697,73.6520740211303,1.86718498095801,0.185560957048395,5.73355097235345,log2_fold_induction,2,0.556682871145185,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.61971260798571,1.61971260798571,1.64844476169785,20,transporter
LTEA_HepaRG_SLCO1B1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_006437.3,SLCO1B1,"solute carrier organic anion transporter family, member 1B1",https://www.ncbi.nlm.nih.gov/gene/10599,,,Active,4.4551420432951,8.209880834639769,59.69386277467062,1.7759296828864,0.180885371867909,4.83423166316995,log2_fold_induction,2,0.542656115603727,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.66836069321711,1.66836069321711,1.65628457016976,20,transporter
LTEA_HepaRG_SULT2A1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_003158.2,SULT2A1,"sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1",https://www.ncbi.nlm.nih.gov/gene/6822,,,Active,13.1731978270358,23.472360379226647,88.1839332806273,1.9453894658214,0.187073897614124,10.2240555363193,log2_fold_induction,2,0.561221692842372,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.77643337763442,1.77643337763442,1.82610915084781,20,transferase
LTEA_HepaRG_TGFA_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_003227.1,TGFA,"transforming growth factor, alpha",https://www.ncbi.nlm.nih.gov/gene/7039,,,Active,3.08740913318917,6.85611067534691,69.98416579188296,1.84499979019863,0.150104983198459,2.31774514020203,log2_fold_induction,2,0.450314949595377,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.55267549768765,1.55267549768765,1.48160102052598,20,growth factor
LTEA_HepaRG_TGFB1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,P01137.2,TGFB1,"transforming growth factor, beta 1",https://www.ncbi.nlm.nih.gov/gene/7040,,,Active,1.09994008012882,3.212501181018715,41.726886116560046,1.62041597654364,0.114131224462307,1.09880661967853,log2_fold_induction,2,0.342393673386921,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.57656496819003,1.57656496819003,1.49908661490502,20,growth factor
LTEA_HepaRG_THRSP_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_003242.1,THRSP,thyroid hormone responsive,https://www.ncbi.nlm.nih.gov/gene/7069,,,Active,3.83230929995348,3.943425341078393,209.56898810624259,2.32132701642811,0.323940818661091,7.23998226265063,log2_fold_induction,2,0.971822455983273,"[""Noisy data"",""Noisy data""]",0.758483601714239,0.758483601714239,-0.85948134734579,20,growth factor
LTEA_HepaRG_TP53_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000537.3,TP53,tumor protein p53,https://www.ncbi.nlm.nih.gov/gene/7157,"[46,46]",,Active,2.10055303907375,5.709716279025485,85.71807958495843,1.93307243261013,0.122630322093241,1.44873992589423,log2_fold_induction,2,0.367890966279723,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.57474272572302,1.57474272572302,1.42499500542474,20,dna binding
LTEA_HepaRG_UGT1A1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000454.1,UGT1A1,"UDP glucuronosyltransferase 1 family, polypeptide A1",https://www.ncbi.nlm.nih.gov/gene/54658,,,Active,4.64931718567961,7.019570594742784,88.85550224880193,1.94868432603333,0.220778803248623,3.34934234955981,log2_fold_induction,2,0.662336409745869,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.85123862877345,1.85123862877345,1.82940400224649,20,transferase
LTEA_HepaRG_UGT1A1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000454.1,UGT1A1,"UDP glucuronosyltransferase 1 family, polypeptide A1",https://www.ncbi.nlm.nih.gov/gene/54658,,,Active,1.31213040531725,1.9810633780810865,9.628994429484946,0.983580935460111,0.220778803248623,1.05497781633345,log2_fold_induction,2,0.662336409745869,"[""Noisy data"",""Hit-call potentially confounded by overfitting"",""Hit-call potentially confounded by overfitting"",""Noisy data""]",0.984620720692912,0.984620720692912,0.864080157842874,20,transferase
LTEA_HepaRG_UGT1A6_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001063.2,UGT1A6,"UDP glucuronosyltransferase 1 family, polypeptide A6",https://www.ncbi.nlm.nih.gov/gene/54578,,,Active,2.58702518493536,4.586749380291239,50.657930472009475,1.70464744358826,0.188007160804812,3.34485564124089,log2_fold_induction,2,0.564021482414436,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.63530439526033,1.63530439526033,1.58535780712066,20,transferase
LTEA_HepaRG_XBP1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_005071.2,XBP1,X-box binding protein 1,https://www.ncbi.nlm.nih.gov/gene/7494,,,Active,0.739918963180326,1.4288118728847223,58.83012278726498,1.76959975482593,0.172618704445313,0.593740402489665,log2_fold_induction,2,0.517856113335939,"[""Borderline active"",""Only highest conc above baseline, active"",""Borderline active"",""Only highest conc above baseline, active""]",1.90879362706774,1.90879362706774,1.40840117253313,20,dna binding
NVS_ADME_hCYP2C9,"Data from the assay component NVS_ADME_hCYP2C9 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C9, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_000762.2,CYP2C9,"cytochrome P450, family 2, subfamily C, polypeptide 9",https://www.ncbi.nlm.nih.gov/gene/1559,,,Active,73.0757807030836,3.6537890351541797,0.6006194144526781,-0.221400633753098,2.17335298616219,72.8580266006805,percent_activity,1.30102999566398,20,,-0.474829686022106,-0.824640613171004,-0.791940731892146,20,cyp
NVS_ENZ_hAMPKa1,"Data from the assay component NVS_ENZ_hAMPKa1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAMPKa1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PRKAA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",NP_006242.5,PRKAA1,"protein kinase, AMP-activated, alpha 1 catalytic subunit",https://www.ncbi.nlm.nih.gov/gene/5562,,,Active,54.4443976086552,2.72221988043276,26.448777818483652,1.4224056083579,2.00671130764906,54.1128084606345,percent_activity,1.69897000433602,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.39289416899543,1.30922210092981,1.30312382105765,20,kinase
NVS_ENZ_hAurA,"Data from the assay component NVS_ENZ_hAurA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAurA, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene AURKA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",NP_003591.2,AURKA,aurora kinase A,https://www.ncbi.nlm.nih.gov/gene/6790,,,Active,24.2452102585497,1.212260512927485,15.550982329809495,1.19175782789282,1.93486952202312,23.8355167394469,percent_activity,1.69897000433602,20,"[""Borderline active"",""Less than 50% efficacy"",""Less than 50% efficacy"",""Borderline active""]",1.38549423414018,1.0472746254758,0.917113558101629,20,kinase
NVS_ENZ_hBACE,"Data from the assay component NVS_ENZ_hBACE was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hBACE, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene BACE1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""aspartate protease"".",P56817.3,BACE1,beta-site APP-cleaving enzyme 1,https://www.ncbi.nlm.nih.gov/gene/23621,,,Active,98.6188096003331,4.9309404800166545,11.039062601963797,1.04293219621211,2.62973154362416,82.1823439360435,percent_activity,1.69897000433602,20,,0.4262491971725,-0.0573699993976386,0.0530774802145979,20,protease
NVS_ENZ_hCASP5,"Data from the assay component NVS_ENZ_hCASP5 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP5, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""cysteine protease"".",NP_004338.3,CASP5,"caspase 5, apoptosis-related cysteine peptidase",https://www.ncbi.nlm.nih.gov/gene/838,,,Active,33.4279463630313,1.6713973181515651,12.831218890330673,1.10826791375614,2.41734301604722,27.8566219778987,percent_activity,1.69897000433602,20,"[""Hit-call potentially confounded by overfitting"",""Borderline active"",""Less than 50% efficacy"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Borderline active""]",1.28880021999182,0.526623443908548,0.112595709292615,20,protease
NVS_ENZ_hNEK2,"Data from the assay component NVS_ENZ_hNEK2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hNEK2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene NEK2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",NP_002488.1,NEK2,NIMA-related kinase 2,https://www.ncbi.nlm.nih.gov/gene/4751,,,Active,57.7693758702322,2.8884687935116102,40.912987953326635,1.61186119800866,1.28327504467093,48.1411468178954,percent_activity,1.69897000433602,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.57734747141548,1.46857304026036,1.49258088427109,20,kinase
NVS_ENZ_hPTPN1_Activator,"Data from the assay component NVS_ENZ_hPTPN1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",NP_002818.1,PTPN1,"protein tyrosine phosphatase, non-receptor type 1",https://www.ncbi.nlm.nih.gov/gene/5770,,,Active,83.9816971062504,4.077688323703669,0.8803949077205745,-0.0553224781078431,3.43256973230247,82.5425069197311,percent_activity,0.301029995663981,20.5954183938148,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",-0.116359402755987,-0.16216702366612,-0.174620079547593,20,phosphatase
NVS_ENZ_hPTPN9,"Data from the assay component NVS_ENZ_hPTPN9 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN9, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"".",NP_002824.1,PTPN9,"protein tyrosine phosphatase, non-receptor type 9",https://www.ncbi.nlm.nih.gov/gene/5780,,,Active,48.8944710958021,2.444723554790105,32.74460532267125,1.51513976015743,3.3113317023715,40.7453936348409,percent_activity,1.69897000433602,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",1.47281930704802,1.35794577527685,1.26239990564033,20,phosphatase
NVS_ENZ_hPTPRB,"Data from the assay component NVS_ENZ_hPTPRB was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPRB, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPRB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""receptor tyrosine phosphatase"".",NP_002828.3,PTPRB,"protein tyrosine phosphatase, receptor type, B",https://www.ncbi.nlm.nih.gov/gene/5787,,,Active,27.0967741900401,1.3548387095020051,21.297055755192506,1.32831956786808,3.23184960798289,22.5806451612903,percent_activity,1.69897000433602,20,"[""Borderline active"",""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy""]",1.64459877582492,1.14978000525231,0.657591008520787,20,phosphatase
NVS_ENZ_hTie2,"Data from the assay component NVS_ENZ_hTie2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hTie2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene TEK. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",NP_000450.2,TEK,"TEK tyrosine kinase, endothelial",https://www.ncbi.nlm.nih.gov/gene/7010,,,Active,38.4214465714477,1.9210723285723852,7.238867468264695,0.859670625484891,1.2800092838241,38.4101301442139,percent_activity,1.30102999566398,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",0.864133908654235,0.74035706976101,0.740390310101924,20,kinase
NVS_ENZ_hTrkA,"Data from the assay component NVS_ENZ_hTrkA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hTrkA, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene NTRK1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",EAW52902.1,NTRK1,"neurotrophic tyrosine kinase, receptor, type 1",https://www.ncbi.nlm.nih.gov/gene/4914,,,Active,25.5821256070399,1.279106280351995,28.161348547783593,1.44965344780097,1.6248449690126,21.3184392699811,percent_activity,1.69897000433602,20,"[""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Borderline active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Borderline active""]",1.65577092031616,1.21602812930009,1.09477205301412,20,kinase
NVS_GPCR_gLTB4,"Data from the assay component NVS_GPCR_gLTB4 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_gLTB4, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Ltb4r. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",NP_001166306.1,Ltb4r,leukotriene B4 receptor,https://www.ncbi.nlm.nih.gov/gene/100379538,,,Active,53.0436110105764,1.7818006924213974,28.94486775279888,1.46157156964437,4.96161095497277,44.203009188574,percent_activity,1.69897000433602,29.7696657298366,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",1.49930792405024,1.31725017291311,1.12473056634484,20,gpcr
NVS_GPCR_h5HT5A,"Data from the assay component NVS_GPCR_h5HT5A was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_h5HT5A, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HTR5A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",NP_076917.1,HTR5A,"5-hydroxytryptamine (serotonin) receptor 5A, G protein-coupled",https://www.ncbi.nlm.nih.gov/gene/3361,,,Active,57.0606694516975,2.2595486597851298,18.35943301658875,1.26385926501506,4.20885451353248,47.5505578800558,percent_activity,1.69897000433602,25.2531270811949,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.16061136048089,0.700890523561368,0.280737092266769,20,gpcr
NVS_GPCR_hAdoRA2a,"Data from the assay component NVS_GPCR_hAdoRA2a was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdoRA2a, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADORA2A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",NP_000666.2,ADORA2A,adenosine A2a receptor,https://www.ncbi.nlm.nih.gov/gene/135,,,Active,78.5121700003325,3.3427306141882998,13.433545150775823,1.12819063934362,3.91457259857584,65.4268083647583,percent_activity,1.69897000433602,23.487435591455,,0.626201863628723,0.103411077287932,-0.167427614136474,20,gpcr
NVS_GPCR_hAdra2C,"Data from the assay component NVS_GPCR_hAdra2C was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdra2C, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADRA2C. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",NP_000674.2,ADRA2C,adrenoceptor alpha 2C,https://www.ncbi.nlm.nih.gov/gene/152,,,Active,42.3557307771879,1.9096037983587495,32.409940245124375,1.51067823031525,3.69672937859252,35.296442687747,percent_activity,1.69897000433602,22.1803762715551,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.52182618101206,1.38872755025002,1.25215006329075,20,gpcr
NVS_GPCR_hTXA2,"Data from the assay component NVS_GPCR_hTXA2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hTXA2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene TBXA2R. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",NP_001051.1,TBXA2R,thromboxane A2 receptor,https://www.ncbi.nlm.nih.gov/gene/6915,,,Active,141.21977625275,4.28503206008833,8.314933344798245,0.919858772124108,5.49275455712066,117.683146878383,percent_activity,1.69897000433602,32.956527342724,,0.295343014950919,-0.1430055522811,-0.233856197677813,20,gpcr
NVS_NR_hAR,"Data from the assay component NVS_NR_hAR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hAR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/367,"[307,111,19,23,187,117,307,19,23,111,187,117]",,Active,43.5616366293919,1.9894097295021984,7.734884714325025,0.888453845080557,3.64946077416744,43.6971891705466,percent_activity,1.69897000433602,21.8967646450046,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",0.889530738223572,0.778048472457985,0.666209793185909,20,nuclear receptor
NVS_NR_hCAR_Antagonist,"Data from the assay component NVS_NR_hCAR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hCAR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NR1I3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",NP_001070948.1,NR1I3,"nuclear receptor subfamily 1, group I, member 3",https://www.ncbi.nlm.nih.gov/gene/9970,"[8,107,58,8,107,58]","[456,715]",Active,75.9839357176393,3.799196785881965,23.740891088394925,1.37549701569313,3.09255137925133,63.3199464524766,percent_activity,1.69897000433602,20,,1.15428844356325,0.951556238407059,0.90330274915197,20,nuclear receptor
NVS_NR_hFXR_Antagonist,"Data from the assay component NVS_NR_hFXR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hFXR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",NP_001193922.1,NR1H4,"nuclear receptor subfamily 1, group H, member 4",https://www.ncbi.nlm.nih.gov/gene/9971,"[27,61,27,61]",[479],Active,27.0081799045384,1.068351807745319,0.04141075959691747,-1.38288680316765,4.21337174214445,27.8745644599303,percent_activity,-1.15490195998574,25.2802304528667,"[""Borderline active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Borderline active""]",-1.23723055363748,-1.38984270834441,-1.50216711698776,20,nuclear receptor
NVS_NR_hRAR_Antagonist,"Data from the assay component NVS_NR_hRAR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hRAR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene RARA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",NP_000955.1,RARA,"retinoic acid receptor, alpha",https://www.ncbi.nlm.nih.gov/gene/5914,,,Active,41.9599022456687,1.296168790595993,32.72455781905416,1.51487378698621,5.395375271865,34.9665924276169,percent_activity,1.69897000433602,32.37225163119,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active""]",1.65454166590928,1.46147753679048,1.26267523138651,20,nuclear receptor
NVS_NR_mERa,"Data from the assay component NVS_NR_mERa was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_mERa, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Esr1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",,Esr1,estrogen receptor 1 (alpha),https://www.ncbi.nlm.nih.gov/gene/13982,"[200,29,165,53,52,167,112,30,67,200,29,165,53,52,30,67,112,167]",[1181],Active,54.1706117140417,2.086722684956499,0.7066100921273327,-0.150820164065182,4.32661002382395,45.1421764287261,percent_activity,0.301029995663981,25.9596601429437,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy""]",-0.182256120853674,-0.587327937429541,-0.981345597358737,20,nuclear receptor
NVS_NR_rAR,"Data from the assay component NVS_NR_rAR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_rAR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Ar. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_036634.1,Ar,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/24208,"[307,19,23,111,187,117,307,111,19,23,187,117]",,Active,84.6620528946311,2.7279574056964937,27.376007343951496,1.43737010870189,5.17249357326478,70.551710756096,percent_activity,1.69897000433602,31.0349614395887,,1.34397125412499,1.18220576170185,1.0621584748056,20,nuclear receptor
TOX21_ARE_BLA_Agonist_ch2,"Data from the assay component TOX21_ARE_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ARE_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene NFE2L2. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,139.770894506949,4.133775295842953,19.130197335878954,1.28171944997718,5.63532060098133,106.9032864971,percent_activity,1.60205999132796,33.811923605888,"[""Noisy data"",""Noisy data""]",1.02403511149356,0.834268134176283,0.786034538113365,20,channel 2
TOX21_ARE_BLA_agonist_ratio,"Data from the assay component TOX21_ARE_BLA_Agonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_ARE_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NFE2L2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is basic leucine zipper.  ",NP_006155.2,NFE2L2,"nuclear factor, erythroid 2-like 2",https://www.ncbi.nlm.nih.gov/gene/4780,"[61,61]",[478],Active,96.307127752725,4.81535638763625,24.401996754882852,1.38742536503327,2.50978290890691,68.5805646517,percent_activity,1.60205999132796,20,"[""Noisy data"",""Noisy data""]",1.12161405882079,0.89763675882729,0.951254886171403,20,dna binding
TOX21_ARE_BLA_agonist_viability,"TOX21_ARE_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,90.2500924333256,3.049199090717099,66.68972592765219,1.82405893261804,4.93299441089742,57.0609763234,percent_activity,1.95424250943932,29.5979664653845,,1.68228795717634,1.50217615574974,1.38987802380476,20,cell cycle
TOX21_ERa_BLA_Antagonist_ch1,"Data from the assay component TOX21_ERa_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_BLA_Antagonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,24.3037837639611,1.0125052253490816,27.989617953242764,1.44699697056581,4.00060219534206,24.5081469824,percent_activity,1.90308998699194,24.0036131720524,"[""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Borderline active""]",1.68486063827346,1.44565593328818,1.32771660273042,20,channel 1
TOX21_ERa_BLA_Antagonist_ch2,"Data from the assay component TOX21_ERa_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,70.5640927966199,1.8122908334588845,22.84710930101514,1.35883125937154,6.48940110253932,67.5700259442,percent_activity,1.90308998699194,38.9364066152359,,1.38419656791055,1.24110203955688,1.09074983479406,20,channel 2
TOX21_ERa_BLA_Antagonist_ratio,"Data from the assay component TOX21_ERa_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2,ESR1,estrogen receptor 1,https://www.ncbi.nlm.nih.gov/gene/2099,"[200,29,165,53,52,167,112,30,67,200,29,165,53,52,30,67,112,167]",[1181],Active,81.930373566668,4.0965186783334,23.549126660921885,1.3719748055891,3.3294568553358,80.9235398991,percent_activity,1.90308998699194,20,,1.2475160945321,1.15456280063981,1.13003112071857,20,nuclear receptor
TOX21_ERb_BLA_Agonist_viability,"TOX21_ERb_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,43.2317261115122,2.103756283858276,13.255225345502993,1.12238711535667,3.42496311979521,41.1969245754,percent_activity,1.60205999132796,20.5497787187713,"[""Cell viability assay fit with gnls winning model"",""Less than 50% efficacy"",""Cell viability assay fit with gnls winning model"",""Less than 50% efficacy""]",1.11052123123863,0.982296412758426,0.858284274505966,20,cell cycle
TOX21_ERb_BLA_Antagonist_ch1,"Data from the assay component TOX21_ERb_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Antagonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,61.5275413114993,2.111361252007692,38.89575423780863,1.5899021974253,4.85686199310144,33.1923312043,percent_activity,1.60205999132796,29.1411719586086,"[""Borderline active"",""Less than 50% efficacy"",""Only one conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.58417029092236,1.52637433188435,1.47062188078851,20,channel 1
TOX21_ERb_BLA_Antagonist_ch2,"Data from the assay component TOX21_ERb_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,48.0105466758788,1.312396989303017,61.29917714852586,1.78745464479161,6.09705587907717,46.1915984065,percent_activity,1.60205999132796,36.582335274463,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",3.4717651779733,1.08479364210176,-1.39335371816287,20,channel 2
TOX21_ERb_BLA_Antagonist_ratio,"Data from the assay component TOX21_ERb_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_001428.1,ESR2,estrogen receptor 2 (ER beta),https://www.ncbi.nlm.nih.gov/gene/2100,,,Active,78.8564541144772,3.251472208986706,26.70706179541503,1.42662611129999,4.04208970819059,59.7125965538,percent_activity,1.60205999132796,24.2525382491435,,1.28081327512576,1.12024735458407,1.03186300353202,20,nuclear receptor
TOX21_ERb_BLA_Antagonist_viability,"TOX21_ERb_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,38.2015312883177,1.8130803198951582,19.731590018646184,1.29516208314884,3.51166013525229,44.7640014253,percent_activity,1.60205999132796,21.0699608115137,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.30639540202999,1.24274692191415,1.17588176892157,20,cell cycle
TOX21_ERR_Antagonist,"Data from the assay component TOX21_ERR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",NP_004442.3,ESRRA,estrogen-related receptor alpha,https://www.ncbi.nlm.nih.gov/gene/2101,,,Active,26.435975132116,1.2510546842788712,31.363500345422732,1.49642452645718,3.52182515338437,21.4984296706,percent_activity,0.903089986991944,21.1309509203062,"[""Borderline active"",""Less than 50% efficacy"",""Less than 50% efficacy"",""Borderline active""]",3.2826743414251,0.970572368336272,-1.3433381657641,20,nuclear receptor
TOX21_HRE_BLA_Agonist_viability,"TOX21_HRE_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,97.4405034694301,4.8720251734715045,14.236069554661675,1.1533901012152,3.0508964104962,87.0035601288,percent_activity,1.90308998699194,20,,0.69125364223924,0.379660835865801,0.403327806909266,20,cell cycle
TOX21_p53_BLA_p1_ch1,"Data from the assay component TOX21_p53_BLA_p1_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p1_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,59.2943662180596,2.96471831090298,64.07113803540918,1.80666243802509,3.00976293237186,40.6501273026,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.66749050860958,1.4528667678586,1.35387130736506,20,channel 1
TOX21_p53_BLA_p1_ch2,"Data from the assay component TOX21_p53_BLA_p1_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p1_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,53.1818289874517,2.659091449372585,84.62541625101342,1.92750081788314,1.71156233629626,33.8157732501,percent_activity,1.95424250943932,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.90001702720961,1.80610661976007,1.80822050402619,20,channel 2
TOX21_p53_BLA_p1_ratio,"Data from the assay component TOX21_p53_BLA_p1_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p1_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.",NP_000537.3,TP53,tumor protein p53,https://www.ncbi.nlm.nih.gov/gene/7157,"[46,46]",,Active,114.972724424627,5.74863622123135,88.46081271267656,1.94675092502917,1.19928273802848,61.1154879614,percent_activity,1.95424250943932,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.80768719394021,1.64033944546483,1.75061343842914,20,dna binding
TOX21_p53_BLA_p1_viability,"TOX21_p53_BLA_p1_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,75.2351436478392,1.7933367810271361,58.81345866111884,1.76947671984195,6.99210027956454,62.2080032063,percent_activity,1.95424250943932,41.9526016773872,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.8060639696866,1.61928058983674,1.42222913544047,20,cell cycle
TOX21_p53_BLA_p2_ch1,"Data from the assay component TOX21_p53_BLA_p2_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p2_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,30.5252136433535,1.526260682167675,47.15479707761558,1.67352588028362,2.8966141715805,25.437678067,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.7946209017585,1.49972325227715,1.25905529101507,20,channel 1
TOX21_p53_BLA_p2_viability,"TOX21_p53_BLA_p2_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,55.9631754900058,1.585767090918457,73.68296201318472,1.86736707593099,5.8818195738939,46.6360155199,percent_activity,1.95424250943932,35.2909174433634,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.89640216797432,1.82527020822065,1.74808383245444,20,cell cycle
TOX21_p53_BLA_p3_ch1,"Data from the assay component TOX21_p53_BLA_p3_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p3_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,33.5077900106791,1.631268268758563,48.89981993561725,1.68930725991888,3.42349065166122,27.923158353,percent_activity,1.95424250943932,20.5409439099673,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.78909174771035,1.51220209082852,1.21270439073944,20,channel 1
TOX21_p53_BLA_p3_viability,"TOX21_p53_BLA_p3_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,55.5465754064478,1.8429062193278751,45.348651451972664,1.65656437682776,5.02345831309728,52.9986790501,percent_activity,1.95424250943932,30.1407498785837,,1.67332605991805,1.55966382833951,1.44106248126725,20,cell cycle
TOX21_p53_BLA_p4_ch1,"Data from the assay component TOX21_p53_BLA_p4_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p4_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,24.60351359144,1.230175679572,43.58225025689183,1.63930965016267,2.74402988187153,24.5300730534,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.71905222768807,1.60198760151915,1.52002932634072,20,channel 1
TOX21_p53_BLA_p4_viability,"TOX21_p53_BLA_p4_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,48.0137411801243,2.0062395234723143,45.44930355265002,1.65752723265021,3.98870130064896,40.0114509855,percent_activity,1.95424250943932,23.9322078038938,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.65599804216876,1.38641827286732,1.11735034599128,20,cell cycle
TOX21_p53_BLA_p5_ch1,"Data from the assay component TOX21_p53_BLA_p5_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p5_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,55.4623514554722,2.365604005725538,60.171690129821364,1.77939221032407,3.90755393557242,46.2186262273,percent_activity,1.95424250943932,23.4453236134345,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.74515458154027,1.63471235729792,1.5379656192801,20,channel 1
TOX21_p53_BLA_p5_ch2,"Data from the assay component TOX21_p53_BLA_p5_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p5_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,100.453684821599,5.02268424107995,73.64997311398437,1.86717259263893,1.61374125094707,83.7114042533,percent_activity,1.95424250943932,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.79160809961734,1.70522767492351,1.74789227895356,20,channel 2
TOX21_p53_BLA_p5_ratio,"Data from the assay component TOX21_p53_BLA_p5_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p5_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.",NP_000537.3,TP53,tumor protein p53,https://www.ncbi.nlm.nih.gov/gene/7157,"[46,46]",,Active,155.431751911705,7.77158759558525,71.54410623079883,1.85457386259797,1.35224934572532,129.5264796406,percent_activity,1.95424250943932,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.73612018079675,1.6304295933829,1.71850207837699,20,dna binding
TOX21_PPARd_BLA_antagonist_ratio,"Data from the assay component TOX21_PPARd_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARd_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARD. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_006229.1,PPARD,peroxisome proliferator-activated receptor delta,https://www.ncbi.nlm.nih.gov/gene/5467,"[36,36]",,Active,54.7560379383131,1.508892679369644,44.63450247760888,1.64967069823538,6.04814805441609,43.9797354347,percent_activity,1.90308998699194,36.2888883264965,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.78521073965846,1.50881706352516,1.20880627625222,20,nuclear receptor
TOX21_PPARg_BLA_antagonist_ratio,"Data from the assay component TOX21_PPARg_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARg_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARG. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_056953.2,PPARG,peroxisome proliferator-activated receptor gamma,https://www.ncbi.nlm.nih.gov/gene/5468,"[34,36,58,72,163,72,36,58,34,163]",,Active,68.8884604263151,1.9145167516076527,25.977851896508934,1.41460323649595,5.9970277415496,52.7799740497,percent_activity,1.90308998699194,35.9821664492976,,1.45775904379928,0.912370753784118,0.353462481285845,20,nuclear receptor
TOX21_RT_HEK293_FLO_32hr_viability,"TOX21_RT_HEK293_FLO_32hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,35.531155449473,1.2497804047138845,0.41166051110577095,-0.385460791082157,4.73831980341741,29.6092983778,percent_activity,-0.221848749616356,28.4299188205045,"[""Borderline active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Cell viability assay fit with gnls winning model"",""Only one conc above baseline, active"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Cell viability assay fit with gnls winning model"",""Less than 50% efficacy""]",-0.27750307219859,-0.416993606487046,-0.556461330532089,20,cell cycle
TOX21_RT_HEPG2_GLO_00hr_ctrl_viability,"TOX21_RT_HEPG2_GLO_00hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,82.8570551290211,4.142852756451055,24.869889034653543,1.39567384752385,3.23642796877449,69.047545949,percent_activity,1.47712125471966,20,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Cell viability assay fit with gnls winning model"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Cell viability assay fit with gnls winning model""]",1.3335083431864,1.28604711032206,1.27639353383774,20,cell cycle
TOX21_RT_HEPG2_GLO_08hr_ctrl_viability,"TOX21_RT_HEPG2_GLO_08hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,71.2585939831428,3.56292969915714,24.71055956600271,1.3928825800308,1.79765049419046,59.3821616578,percent_activity,1.47712125471966,20,"[""Cell viability assay fit with gnls winning model"",""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Hit-call potentially confounded by overfitting"",""Cell viability assay fit with gnls winning model"",""Only one conc above baseline, active""]",1.34179049331312,1.25702852759295,1.27360226633997,20,cell cycle
TOX21_RT_HEPG2_GLO_16hr_ctrl_viability,"TOX21_RT_HEPG2_GLO_16hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,61.1026204078376,3.05513102039188,24.710314621687058,1.3928782750497,1.42693580835246,50.9188503404,percent_activity,1.47712125471966,20,"[""Cell viability assay fit with gnls winning model"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Cell viability assay fit with gnls winning model"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.35377333572442,1.25250460065026,1.27359796136561,20,cell cycle
TOX21_RT_HEPG2_GLO_24hr_ctrl_viability,"TOX21_RT_HEPG2_GLO_24hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,50.6260213670551,2.531301068352755,24.92194782881985,1.39658198253968,1.22724010465665,42.1883511403,percent_activity,1.47712125471966,20,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Less than 50% efficacy"",""Cell viability assay fit with gnls winning model"",""Less than 50% efficacy"",""Cell viability assay fit with gnls winning model"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.37344940934902,1.2583904720916,1.27730166885541,20,cell cycle
TOX21_RT_HEPG2_GLO_32hr_ctrl_viability,"TOX21_RT_HEPG2_GLO_32hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,38.5908456071058,1.92954228035529,25.13509860487037,1.40028059330259,1.38797001670782,32.1590380061,percent_activity,1.47712125471966,20,"[""Less than 50% efficacy"",""Only one conc above baseline, active"",""Cell viability assay fit with gnls winning model"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Cell viability assay fit with gnls winning model"",""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",1.40424695072986,1.28560593626217,1.28100024985752,20,cell cycle
TOX21_RXR_BLA_Agonist_ch2,"Data from the assay component TOX21_RXR_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RXR_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene RXRA. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,67.2171011551093,2.284450639498065,4.955211367497771,0.695062184306684,4.90395808901334,80.1681014248,percent_activity,1.30102999566398,29.42374853408,,0.632211774863404,0.375637551409326,0.143406959126075,20,channel 2
TOX21_RXR_BLA_Agonist_ratio,"Data from the assay component TOX21_RXR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RXR_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RXRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where subfamily is NF-kappa B.",NP_002948.1,RXRA,"retinoid X receptor, alpha",https://www.ncbi.nlm.nih.gov/gene/6256,,,Active,42.3201686365303,2.116008431826515,9.492978501939863,0.977402497359323,2.27839049691729,46.1709843575,percent_activity,1.30102999566398,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",0.944390136342456,0.482020935558736,0.316536830520405,20,dna binding
TOX21_TR_LUC_GH3_Antagonist,"Data from the assay component TOX21_TR_LUC_GH3_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.","NP_003241.2|NP_000452.2","THRA | THRB","thyroid hormone receptor, alpha , thyroid hormone receptor, beta","https://www.ncbi.nlm.nih.gov/gene/7067 , https://www.ncbi.nlm.nih.gov/gene/7068",,,Active,39.123163702747,1.7437096049972685,71.67022662450375,1.85533877773054,3.73945711206963,26.5576382394,percent_activity,1.95424250943932,22.4367426724178,"[""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.89716042145112,1.72663497234254,1.54500407772429,20,nuclear receptor